ClinicalTrials.gg
CompletedNCT02819635Updated Jun 30, 2022Results posted

A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

A Phase 2/3 interventional study of Placebo and Upadacitinib in Ulcerative Colitis (UC), sponsored by AbbVie. Completed at 496 sites in 46 countries. Open to participants aged 16 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-06-30.

Sponsored by AbbVie · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
1,302
Allocation
Randomized
Ages
16 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing upadacitinib in Colitis, Ulcerative — 8 open to participants now, 10 under way, 3 of them phase 3. upadacitinib · Colitis, Ulcerative.

Enrollment
Largest of 12
1,302 · median 180
Started
2016
the only one that year
Phase 2/3
Only one
of the 12
Registered
1st of 12
by date
Lead sponsor
4 of 12
AbbVie

Among the 12 studies testing upadacitinib in Colitis, Ulcerative, this one has the largest enrollment, is the only one that started in 2016, is the only one in phase 2/3, and was the 1st registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

8 of the 12 studies testing upadacitinib in Colitis, Ulcerative are open now, in 3 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About upadacitinib

upadacitinib: first FDA approval 2019 (RINVOQ), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 16 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing upadacitinib in Colitis, Ulcerative, or all of them as a file.
02

Study summary

This study was comprised of three substudies. The objective of Substudy 1 was to characterize the dose-response, efficacy, and safety of upadacitinib compared to placebo in inducing clinical remission to identify the induction dose of upadacitinib for further evaluation in Substudy 2. The objective of Substudy 2 was to evaluate the efficacy and safety of upadacitinib compared to placebo in inducing clinical remission in participants. The objective of Substudy 3 was to evaluate the efficacy and safety of upadacitinib compared to placebo in achieving clinical remission in participants who had a response following induction with upadacitinib.

Read the detailed description

Substudy 1 was a Phase 2b dose-ranging study designed to evaluate the efficacy and safety of different oral doses of upadacitinib compared to placebo as 8-week induction therapy in participants with moderately to severely active UC. Approximately 250 participants were planned to be randomized 1:1:1:1:1 to the placebo group and 4 upadacitinib doses (7.5, 15, 30, and 45 mg). Randomization was stratified by previous biologic therapy use (yes/no), Baseline corticosteroid use (yes/no), and Baseline Adapted Mayo score (≤ 7 or > 7). The study duration included a Screening Period of up to 5 weeks and an 8-week double-blind (DB) Induction Period. After all randomized participants completed the 8-week induction, a dose-selection analysis of efficacy and safety (selected laboratory parameters) of upadacitinib versus placebo was performed. Based on this dose-selection analysis, one induction dose (upadacitinib 45 mg) was identified for further evaluation in two Phase 3 induction studies, M14-234 Substudy 2 and M14-675 (NCT03653026). During the analysis period, 132 additional participants were randomized into Groups 3 and 4 of Substudy 1 (upadacitinib 30 mg and 45 mg dose groups; approximately 66 participants per dose group). The objectives of enrolling these additional participants were to avoid interrupting the study activities during the analysis period and to support a sufficient number of participants with clinical response to be re-randomized into the maintenance portion in Substudy 3. Substudy 1 main participants are defined as those first 250 randomized 250, and additional participants are defined as those who were randomized after the main participants.

Substudy 2 was a two-part Phase 3 dose-confirming study designed to evaluate the efficacy and safety of oral administration of upadacitinib 45 mg compared to placebo as induction therapy for up to 16 weeks in participants with moderately to severely active UC. Substudy 2 included a Screening Period of up to 5 weeks, Part 1, and Part 2. Part 1 was a randomized, DB, placebo-controlled 8-week induction period. Part 2 was an open-label, 8-week extended treatment period for clinical non-responders from Part 1 of Substudy 2. Part 1 was planned to enroll 462 subjects; actual enrollment was 474 subjects. Eligible participants were randomized in a 2:1 ratio to one of the two treatment groups (DB upadacitinib 45 mg or matching placebo) for 8 weeks. The randomization was stratified by bio-IR status (Biologic inadequate responders [bio-IR] vs Non-biologic-inadequate responders [non-bio-IR], corticosteroid use (yes or no), and Adapted Mayo score (≤ 7 or > 7) at Baseline. Within bio-IR, the randomization was further stratified by number of prior biologic treatments (≤ 1 or > 1). Within non-bio-IR, the randomization was further stratified by previous biologic use (yes or no). Part 2 was an open label, 8-week Extended Treatment Period for those who did not achieve clinical response per Adapted Mayo score at Week 8 in Part 1. All participants received upadacitinib 45 mg.

Substudy 3 was a Phase 3 maintenance study designed to evaluate the efficacy and safety of upadacitinib 15 and 30 mg once daily (QD) compared to placebo in achieving clinical remission per Adapted Mayo score in participants with moderately to severely active UC who achieved clinical response per Adapted Mayo score following induction therapy from Substudy 1, Substudy 2, or Study M14-675. A total of 1,046 subjects who achieved clinical response per Adapted Mayo score after completion of induction treatment or Extended Treatment Period in Study M14-234 Substudy 1, Substudy 2, or Study M14-675 entered Substudy 3, and 1,044 were treated with a blinded treatment assignment for up to 52 weeks. Substudy 3 included 4 cohorts. Cohort 1: 847 participants who achieved clinical response in Substudy 1, Substudy 2, or Study M14-675 at either Week 8 or Week 16, and received upadacitinib 15, 30, or 45 mg QD. The treatment groups in Cohort 1 were Group 1: upadacitinib 15 mg QD; Group 2: upadacitinib 30 mg QD; and Group 3: placebo QD. Those who achieved clinical response and received upadacitinib 15 mg QD in Substudy 1 were re-randomized 1:1 to only receive upadacitinib 15 mg QD or placebo QD (treatment Group 1 or 3). Cohort 2: 104 participants who received double-blind placebo QD treatment for 8 weeks during Substudy 1, Substudy 2 Part 1, or Study M14-675 Part 1 and achieved clinical response at Week 8 continued to receive blinded placebo QD in Substudy 3. Cohort 3: 75 participants who received upadacitinib 45 mg QD in Induction Phase and did not achieve clinical response and received upadacitinib 45 mg QD in Extended Treatment in Substudy 2 Part 2 or in Study M14-675 Part 2 and achieved clinical response at Week 16 were re-randomized 1:1 and received blinded upadacitinib 30 mg QD or upadacitinib 15 mg QD in Substudy 3. Cohort 4: 20 participants who received double-blinded treatment of upadacitinib 7.5 mg QD for 8 weeks during Substudy 1 and achieved clinical response at Week 8 continued to receive blinded treatment of upadacitinib 7.5 mg QD in Substudy 3.

03

Conditions studied

  • Ulcerative Colitis (UC)

Browse trials for

Keywords

  • Upadacitinib (ABT-494)
  • Moderately to Severely Active UC
  • RINVOQ
04

Who can participate

Ages eligible
16 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Note: Adolescent participants who are 16 or 17 years old will be eligible to participate if approved by the country or regulatory/health authority. If approval has not been granted, only participants ≥18 years old will be enrolled. Adolescents must weigh ≥ 40 kilograms and meet the definition of Tanner Stage 5 at Screening Visit.

  • Diagnosis of ulcerative colitis for 90 days or greater prior to Baseline, confirmed by colonoscopy during the Screening Period, with exclusion of current infection, colonic dysplasia and/or . Appropriate documentation of results consistent with the diagnosis of UC, in the assessment of the Investigator, must be available.
  • Active ulcerative colitis with an Adapted Mayo score of 5 to 9 points and endoscopic sub score of 2 to 3 (confirmed by central reader).
  • Demonstrated an inadequate response to, loss of response to, or intolerance to at least one of the following treatments including: oral aminosalicylates, , , and/or biologic therapies in the opinion of the investigator.

Note: Participants who have had inadequate response, loss of response to conventional therapy, but have not failed biologic therapy (Non-bio-IR) and have received a prior biologic for up to 1 year may be enrolled, however they must have discontinued the biologic for reasons other than inadequate response or intolerance (e.g., change of insurance, well controlled disease) and must meet criteria for inadequate response, loss of response or intolerance to aminosalicylates, corticosteroids, and/or immunosuppressants as defined above.

  • If female, participant must meet the criteria for Recommendations
  • Female participants of must have a negative serum pregnancy test at the Screening Visit and a negative urine pregnancy test at the Baseline Visit prior to study drug dosing.

Exclusion criteria

Exclusion Criteria:

  • Participant with current diagnosis of Crohn's disease (CD) or diagnosis of indeterminate colitis (IC)
  • Current diagnosis of fulminant colitis and/or toxic megacolon
  • Participant with disease limited to the rectum (ulcerative proctitis) during the screening endoscopy
  • Received cyclosporine, tacrolimus, mycophenolate mofetil, or thalidomide within 30 days prior to Baseline
  • Participant on azathioprine or 6-mercaptopurine within 10 days of Baseline
  • Received intravenous within 14 days prior to Screening or during the Screening Period.
  • Participant with previous exposure to Janus Activated Kinase (JAK) inhibitor (e.g., tofacitinib, baricitinib, filgotinib, upadacitinib).
  • Screening laboratory and other analyses show any abnormal results meeting the exclusion criteria
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,302 participants (actual)

Study arms

  • Placebo comparator
    SS1: Placebo

    During the 8-week induction phase in Substudy 1, participants received placebo for upadacitinib film-coated tablets once daily by mouth (QD) for 8 weeks.

    Drug: Placebo

  • Experimental
    SS1: Upadacitinib 7.5 mg

    During the 8-week induction phase in Substudy 1, participants received 7.5 mg upadacitinib film-coated tablets once daily by mouth (QD) for 8 weeks.

    Drug: Upadacitinib

  • Experimental
    SS1: Upadacitinib 15 mg

    During the 8-week induction phase in Substudy 1, participants received 15 mg upadacitinib film-coated tablets once daily by mouth (QD) for 8 weeks.

    Drug: Upadacitinib

  • Experimental
    SS1: Upadacitinib 30 mg

    During the 8-week induction phase in Substudy 1, participants received 30 mg upadacitinib film-coated tablets once daily by mouth (QD) for 8 weeks. Additional participants were enrolled during the Substudy 1 analysis period and received 30 mg upadacitinib film-coated tablets once daily by mouth (QD) for 4 weeks.

    Drug: Upadacitinib

  • Experimental
    SS1: Upadacitinib 45 mg

    During the 8-week induction phase in Substudy 1, participants received 45 mg upadacitinib film-coated tablets once daily by mouth (QD) for 8 weeks. Additional participants were enrolled during the Substudy 1 analysis period and received 45 mg upadacitinib film-coated tablets once daily by mouth (QD) for 4 weeks.

    Drug: Upadacitinib

  • Experimental
    SS2: Placebo/Upadacitinib 45 mg

    During the Substudy 2 Part 1 induction period, participants received placebo for upadacitinib film-coated tablets once daily by mouth (QD) for 8 weeks. Participants who did not achieve clinical response at Week 8 of Part 1 were enrolled in an open-label extended treatment period and received 45 mg upadacitinib film-coated tablets once daily by mouth (QD) for an additional 8 weeks.

    Drug: Placebo · Drug: Upadacitinib

  • Experimental
    SS2: Upadacitinib 45 mg/Upadacitinib 45 mg

    During the Substudy 2 Part 1 induction period, participants received 45 mg upadacitinib film-coated tablets once daily by mouth (QD) for 8 weeks. Participants who did not achieve clinical response at Week 8 of Part 1 were enrolled in an open-label expended treatment period and received 45 mg upadacitinib film-coated tablets once daily by mouth (QD) for an additional 8 weeks.

    Drug: Upadacitinib

  • Experimental
    SS3: M14-675 clinical responders

    Participants in Study M14-675 (NCT03653026) who achieved clinical response defined by Adapted Mayo Score at Week 8 or Week 16 in that study and did not meet any study discontinuation criteria were eligible to enroll into Substudy 3. Participants were re-randomized and treated with a blinded treatment assignment (15 mg upadacitinib film-coated tablets once daily by mouth \[QD\], or 30 mg upadacitinib film-coated tablets QD, or placebo for upadacitinib film-coated tablets QD) for up to 52 weeks.

    Drug: Placebo · Drug: Upadacitinib

Interventions

  • DrugPlacebo

    Film-coated tablet for oral administration

  • Film-coated tablet for oral administration

    Also known as: ABT-494, RINVOQ

06

What researchers measure

Primary outcomes

  1. Substudy 1: Percentage Of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 8

    The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal) 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed) 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration) The overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease. For Substudy 1, clinical remission is defined as SFS ≤ 1, RBS of 0, and endoscopic subscore ≤ 1.

    Time frame: At Week 8

  2. Substudy 2: Percentage Of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 8

    The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal) 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed) 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration) The overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease. For Substudy 2, clinical remission is defined as SFS ≤ 1 and not greater than Baseline, RBS of 0, and endoscopic subscore ≤ 1. In Substudy 2, evidence of friability during endoscopy in participants with otherwise "mild" endoscopic activity conferred an endoscopic subscore of 2.

    Time frame: At Week 8

  3. Substudy 3: Percentage Of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 52

    The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed). 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). The overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease. For Substudy 3, clinical remission is defined as SFS ≤ 1 and not greater than Baseline, RBS of 0, and endoscopic subscore ≤ 1. In addition, evidence of friability during endoscopy in participants with otherwise "mild" endoscopic activity conferred an endoscopic subscore of 2.

    Time frame: At Week 52

Secondary outcomes

  1. Substudy 1: Percentage Of Participants With Endoscopic Improvement at Week 8

    Endoscopic improvement is defined as an endoscopic subscore of 0 or 1. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).

    Time frame: At Week 8

  2. Substudy 1: Percentage Of Participants Achieving Clinical Remission Per Full Mayo Score at Week 8

    The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The Full Mayo score (FMS) ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Clinical remission per FMS is defined as Mayo Score ≤ 2 and no individual subscore \> 1.

    Time frame: At Week 8

  3. Substudy 1: Percentage Of Participants Achieving Clinical Response Per Adapted Mayo Score at Week 8

    The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed). 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). The overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease. Clinical response is defined as a decrease from baseline in the Adapted Mayo score ≥ 2 points and ≥ 30% from baseline, and a decrease in RBS ≥ 1 or an absolute RBS ≤ 1).

    Time frame: At Week 8

  4. Substudy 1: Percentage Of Participants Achieving Clinical Response Per Partial Mayo Score at Week 2

    The Partial Mayo Score is a composite score of UC disease activity based on the following 2 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed). The overall Partial Mayo score ranges from 0 to 6 with higher scores representing more severe disease. Clinical response per Partial Mayo Score is defined as a decrease in Partial Adapted Mayo score ≥ 2 points and ≥ 30% from Baseline, plus a decrease in RBS ≥ 1 or an absolute RBS ≤ 1.

    Time frame: At Week 2

  5. Substudy 1: Change in Full Mayo Score From Baseline to Week 8

    The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The Full Mayo score (FMS) ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Clinical remission per FMS is defined as Mayo Score ≤ 2 and no individual subscore \> 1.

    Time frame: Baseline (Week 0), Week 8

  6. Substudy 1: Percentage Of Participants With Endoscopic Remission at Week 8

    Endoscopic remission is defined as an endoscopic subscore of 0. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).

    Time frame: At Week 8

  7. Substudy 1: Percentage Of Participants Who Achieved Histologic Improvement at Week 8

    The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration. Histologic improvement was defined as decrease from baseline in Geboes score.

    Time frame: At Week 8

  8. Substudy 2: Percentage Of Participants With Endoscopic Improvement at Week 8

    Endoscopic improvement is defined as an endoscopic subscore of 0 or 1. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).

    Time frame: At Week 8

  9. Substudy 2: Percentage Of Participants With Endoscopic Remission at Week 8

    Endoscopic remission is defined as an endoscopic subscore of 0. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).

    Time frame: At Week 8

  10. Substudy 2: Percentage Of Participants Achieving Clinical Response Per Adapted Mayo Score at Week 8

    The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed). 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). The overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease. Clinical response is defined as a decrease from baseline in the Adapted Mayo score ≥ 2 points and ≥ 30% from baseline, and a decrease in RBS ≥ 1 or an absolute RBS ≤ 1).

    Time frame: At Week 8

  11. Substudy 2: Percentage Of Participants Achieving Clinical Response Per Partial Mayo Score at Week 2

    The Partial Mayo Score is a composite score of UC disease activity based on the following 2 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed). The overall Partial Mayo score ranges from 0 to 6 with higher scores representing more severe disease. Clinical response per Partial Mayo Score is defined as a decrease from Baseline ≥ 1 point and ≥ 30% from Baseline, plus a decrease in RBS ≥ 1 or an absolute RBS ≤ 1.

    Time frame: At Week 2

  12. Substudy 2: Percentage Of Participants Who Achieved Histologic-Endoscopic Mucosal Improvement at Week 8

    Histologic-endoscopic mucosal improvement is defined as an endoscopic subscore of 0 or 1 and a Geboes score ≤ 3.1. The endoscopic subscore ranges from 0 (normal or inactive disease) to 3 (severe disease with spontaneous bleeding, ulceration). The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration.

    Time frame: At Week 8

  13. Substudy 2: Percentage Of Participants Who Report No Bowel Urgency at Week 8

    Bowel urgency was assessed by participants in a subject diary completed once a day.

    Time frame: At Week 8

  14. Substudy 2: Percentage Of Participants Who Reported No Abdominal Pain at Week 8

    Abdominal pain was assessed by participants in a subject diary completed once a day.

    Time frame: At Week 8

  15. Substudy 2: Percentage Of Participants Who Achieved Histologic Improvement at Week 8

    The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration. Histologic improvement was defined as decrease from baseline in Geboes score.

    Time frame: At Week 8

  16. Substudy 2: Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score at Week 8

    The Inflammatory Bowel Disease Questionnaire (IBDQ) is used to assess health-related quality of life (HRQoL) in patients with ulcerative colitis. It consists of 32 questions evaluating bowel and systemic symptoms, as well as emotional and social functions. Each question is answered on a scale from 1 (worst) to 7 (best). The total score ranges from 32 to 224 with higher scores indicating better health-related quality of life. A positive change from Baseline indicates improvement.

    Time frame: Baseline (Week 0), Week 8

  17. Substudy 2: Percentage Of Participants With Mucosal Healing at Week 8

    Mucosal healing is defined as an endoscopic score of 0 and Geboes score \< 2.0. The endoscopic subscore ranges from 0 (normal or inactive disease) to 3 (severe disease with spontaneous bleeding, ulceration). The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration.

    Time frame: At Week 8

  18. Substudy 2: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 8

    The FACIT fatigue questionnaire was developed to assess fatigue associated with anemia. It consists of 13 fatigue-related questions. Each question is answered on a 5-point Likert scale: 0 (not at all); 1 (a little bit); 2 (somewhat); 3 (quite a bit); and 4 (very much). The total score ranges from 0 to 52, where higher scores represent less fatigue, and a positive change from Baseline indicates improvement.

    Time frame: Baseline (Week 0), Week 8

  19. Substudy 3: Percentage Of Participants With Endoscopic Improvement at Week 52

    Endoscopic improvement is defined as an endoscopic subscore of 0 or 1. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).

    Time frame: At Week 52

  20. Substudy 3: Percentage of Participants With Clinical Remission Per Adapted Mayo Score at Week 52 Among Those Who Achieved Clinical Remission at the End of the Induction Treatment

    The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed). 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). The overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease. For Substudy 3, clinical remission is defined as SFS ≤ 1 and not greater than Baseline, RBS of 0, and endoscopic subscore ≤ 1. In addition, evidence of friability during endoscopy in participants with otherwise "mild" endoscopic activity conferred an endoscopic subscore of 2.

    Time frame: At Week 52

  21. Substudy 3: Percentage of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Wk 52 and Were Corticosteroid Free for ≥ 90 Days Immediately Preceding Wk 52 Among Those Who Achieved Clinical Remission at the End of the Induction Treatment

    The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed). 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). The overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease. For Substudy 3, clinical remission is defined as SFS ≤ 1 and not greater than Baseline, RBS of 0, and endoscopic subscore ≤ 1. In addition, evidence of friability during endoscopy in participants with otherwise "mild" endoscopic activity conferred an endoscopic subscore of 2.

    Time frame: At Week 52

  22. Substudy 3: Percentage of Participants With Endoscopic Improvement at Wk 52 Among Those Who Achieved Endoscopic Improvement at the End of the Induction Treatment

    Endoscopic improvement is defined as an endoscopic subscore of 0 or 1. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).

    Time frame: At Week 52

  23. Substudy 3: Percentage Of Participants With Endoscopic Remission At Week 52

    Endoscopic remission is defined as an endoscopic subscore of 0. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).

    Time frame: At Week 52

  24. Substudy 3: Percentage Of Participants Who Maintained Clinical Response Per Adapted Mayo Score at Wk 52 Among Those Who Achieved Clinical Response at the End of the Induction Treatment

    The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed). 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). The overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease. Clinical response is defined as a decrease from baseline in the Adapted Mayo score ≥ 2 points and ≥ 30% from baseline, and a decrease in RBS ≥ 1 or an absolute RBS ≤ 1).

    Time frame: At Week 52

  25. Substudy 3: Percentage Of Participants Who Achieved Histologic-Endoscopic Mucosal Improvement at Week 52

    Histologic-endoscopic mucosal improvement is defined as an endoscopic subscore of 0 or 1 and a Geboes score ≤ 3.1. The endoscopic subscore ranges from 0 (normal or inactive disease) to 3 (severe disease with spontaneous bleeding, ulceration). The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration.

    Time frame: At Week 52

  26. Substudy 3: Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score at Week 52

    The Inflammatory Bowel Disease Questionnaire (IBDQ) is used to assess health-related quality of life (HRQoL) in patients with ulcerative colitis. It consists of 32 questions evaluating bowel and systemic symptoms, as well as emotional and social functions. Each question is answered on a scale from 1 (worst) to 7 (best). The total score ranges from 32 to 224 with higher scores indicating better health-related quality of life. A positive change from Baseline indicates improvement.

    Time frame: Baseline (Week 0), Week 52

  27. Substudy 3: Percentage Of Participants With Mucosal Healing at Week 52

    Mucosal healing is defined as an endoscopic score of 0 and Geboes score \< 2.0. The endoscopic subscore ranges from 0 (normal or inactive disease) to 3 (severe disease with spontaneous bleeding, ulceration). The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration.

    Time frame: At Week 52

  28. Substudy 3: Percentage Of Participants Who Reported No Bowel Urgency at Week 52

    Bowel urgency was assessed by participants in a subject diary completed once a day.

    Time frame: At Week 52

  29. Substudy 3: Percentage Of Participants Who Reported No Abdominal Pain at Week 52

    Abdominal pain was assessed by participants in a subject diary completed once a day.

    Time frame: At Week 52

  30. Substudy 3: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 52

    The FACIT fatigue questionnaire was developed to assess fatigue associated with anemia. It consists of 13 fatigue-related questions. Each question is answered on a 5-point Likert scale: 0 (not at all); 1 (a little bit); 2 (somewhat); 3 (quite a bit); and 4 (very much). The total score ranges from 0 to 52, where higher scores represent less fatigue, and a positive change from Baseline indicates improvement.

    Time frame: Baseline (Week 0), Week 52

07

Results

Posted Jun 30, 2022

Participant flow

Substudy 1 and Substudy 2, Part 1
Participant flow — Substudy 1 and Substudy 2, Part 1
MilestoneSS1: PlaceboSS1: Upadacitinib 7.5 mgSS1: Upadacitinib 15 mgSS1: Upadacitinib 30 mgSS1: Upadacitinib 45 mgSS2: Placebo/Upadacitinib 45 mgSS2: Upadacitinib 45 mg/Upadacitinib 45 mgSS3: M14-675 Clinical RespondersSS3: PlaceboSS3: UPA 7.5 mgSS3: UPA 15 mgSS3: UPA 30 mg
Started4647491171231553194460000
Completed4145451051131353064460000
Not completed5241210201300000
Withdrew: Adverse event313549600000
Withdrew: Withdrew consent000013200000
Withdrew: Lost to follow-up000001100000
Withdrew: Covid-19 logistical restrictions000000100000
Withdrew: Other, not specified211757300000
Substudy 2, Part 2
Participant flow — Substudy 2, Part 2
MilestoneSS1: PlaceboSS1: Upadacitinib 7.5 mgSS1: Upadacitinib 15 mgSS1: Upadacitinib 30 mgSS1: Upadacitinib 45 mgSS2: Placebo/Upadacitinib 45 mgSS2: Upadacitinib 45 mg/Upadacitinib 45 mgSS3: M14-675 Clinical RespondersSS3: PlaceboSS3: UPA 7.5 mgSS3: UPA 15 mgSS3: UPA 30 mg
Started00000855900000
Completed00000744700000
Not completed00000111200000
Withdrew: Adverse event000004000000
Withdrew: Withdrew consent000003100000
Withdrew: Lost to follow-up000000100000
Withdrew: Covid-19 logistical restrictions000000200000
Withdrew: Other, not specified000004800000
Substudy 3
Participant flow — Substudy 3
MilestoneSS1: PlaceboSS1: Upadacitinib 7.5 mgSS1: Upadacitinib 15 mgSS1: Upadacitinib 30 mgSS1: Upadacitinib 45 mgSS2: Placebo/Upadacitinib 45 mgSS2: Upadacitinib 45 mg/Upadacitinib 45 mgSS3: M14-675 Clinical RespondersSS3: PlaceboSS3: UPA 7.5 mgSS3: UPA 15 mgSS3: UPA 30 mg
Started0000000038620324316
Completed0000000014011218248
Not completed00000000246910668
Withdrew: Adverse event000000003231218
Withdrew: Withdrew consent0000000011149
Withdrew: Lost to follow-up000000001011
Withdrew: Covid-19 logistical restrictions000000000001
Withdrew: Other, not specified0000000020258939

Outcome measures

PrimarySubstudy 1: Percentage Of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 8

The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal) 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed) 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration) The overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease. For Substudy 1, clinical remission is defined as SFS ≤ 1, RBS of 0, and endoscopic subscore ≤ 1.

Time frame:
At Week 8
Reported as:
Number · percentage of participants
Substudy 1: Percentage Of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 8
percentage of participantsSS1: PlaceboSS1: Upadacitinib 7.5 mgSS1: Upadacitinib 15 mgSS1: Upadacitinib 30 mgSS1: Upadacitinib 45 mg
Substudy 1: Percentage Of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 808.514.313.521.4
Statistical analysis
  • SS1: Placebo vs SS1: Upadacitinib 7.5 mg · Cochran-Mantel-Haenszel · p = 0.049 (The primary and ranked secondary efficacy endpoints were tested with multiplicity adjustment using a fixed-sequence multiple testing procedure to ensure a strong control of family-wise type I error rate at significance level alpha = 0.05 (2-sided).) · Adjusted risk difference (%): 8.4 · 95% CI 0.0 to 16.8Difference = Upadacitinib 7.5 mg - Placebo
  • SS1: Placebo vs SS1: Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = 0.010 (The primary and ranked secondary efficacy endpoints were tested with multiplicity adjustment using a fixed-sequence multiple testing procedure to ensure a strong control of family-wise type I error rate at significance level alpha = 0.05 (2-sided).) · Adjusted risk difference (%): 13.5 · 95% CI 3.3 to 23.8Difference = Upadacitinib 15 mg - Placebo
  • SS1: Placebo vs SS1: Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = 0.007 (The primary and ranked secondary efficacy endpoints were tested with multiplicity adjustment using a fixed-sequence multiple testing procedure to ensure a strong control of family-wise type I error rate at significance level alpha = 0.05 (2-sided).) · Adjusted risk difference (%): 13.8 · 95% CI 3.8 to 23.9Difference = Upadacitinib 30 mg - Placebo
  • SS1: Placebo vs SS1: Upadacitinib 45 mg · Cochran-Mantel-Haenszel · p = <0.001 (The primary and ranked secondary efficacy endpoints were tested with multiplicity adjustment using a fixed-sequence multiple testing procedure to ensure a strong control of family-wise type I error rate at significance level alpha = 0.05 (2-sided).) · Adjusted risk difference (%): 21.1 · 95% CI 8.6 to 33.6Difference = Upadacitinib 45 mg - Placebo
PrimarySubstudy 2: Percentage Of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 8

The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal) 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed) 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration) The overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease. For Substudy 2, clinical remission is defined as SFS ≤ 1 and not greater than Baseline, RBS of 0, and endoscopic subscore ≤ 1. In Substudy 2, evidence of friability during endoscopy in participants with otherwise "mild" endoscopic activity conferred an endoscopic subscore of 2.

Time frame:
At Week 8
Reported as:
Number · percentage of participants
Substudy 2: Percentage Of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 8
percentage of participantsSS2: PlaceboSS2: Upadacitinib 45 mg
Substudy 2: Percentage Of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 84.826.1
Statistical analysis
  • SS2: Placebo vs SS2: Upadacitinib 45 mg · Cochran-Mantel-Haenszel · p = <0.001 (The primary and ranked secondary efficacy endpoints were tested with multiplicity adjustment using a fixed-sequence multiple testing procedure to ensure a strong control of family-wise type I error rate at significance level alpha = 0.05 (2-sided).) · Adjusted risk difference (%): 21.6 · 95% CI 15.8 to 27.4Difference = Upadacitinib 45 mg - Placebo
PrimarySubstudy 3: Percentage Of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 52

The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed). 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). The overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease. For Substudy 3, clinical remission is defined as SFS ≤ 1 and not greater than Baseline, RBS of 0, and endoscopic subscore ≤ 1. In addition, evidence of friability during endoscopy in participants with otherwise "mild" endoscopic activity conferred an endoscopic subscore of 2.

Time frame:
At Week 52
Reported as:
Number · percentage of participants
Substudy 3: Percentage Of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 52
percentage of participantsSS3: PlaceboSS3: UPA 15 mgSS3: UPA 30 mg
Substudy 3: Percentage Of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 5212.1 (6.9 to 17.4)42.3 (34.3 to 50.3)51.7 (43.6 to 59.8)
Statistical analysis
  • SS3: Placebo vs SS3: UPA 15 mg · Cochran-Mantel-Haenszel · p = <0.001 (The primary and ranked secondary efficacy endpoints were tested with multiplicity adjustment using a fixed-sequence multiple testing procedure to ensure a strong control of family-wise type I error rate at significance level alpha = 0.05 (2-sided).) · Adjusted risk difference (%): 30.7 · 95% CI 21.7 to 39.8Difference = Upadacitinib 15 mg - Placebo
  • SS3: Placebo vs SS3: UPA 30 mg · Cochran-Mantel-Haenszel · p = <0.001 (The primary and ranked secondary efficacy endpoints were tested with multiplicity adjustment using a fixed-sequence multiple testing procedure to ensure a strong control of family-wise type I error rate at significance level alpha = 0.05 (2-sided).) · Adjusted risk difference (%): 39.0 · 95% CI 29.7 to 48.2Difference = Upadacitinib 30 mg - Placebo
SecondarySubstudy 1: Percentage Of Participants With Endoscopic Improvement at Week 8

Endoscopic improvement is defined as an endoscopic subscore of 0 or 1. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).

Time frame:
At Week 8
Reported as:
Number · percentage of participants
Substudy 1: Percentage Of Participants With Endoscopic Improvement at Week 8
percentage of participantsSS1: PlaceboSS1: Upadacitinib 7.5 mgSS1: Upadacitinib 15 mgSS1: Upadacitinib 30 mgSS1: Upadacitinib 45 mg
Substudy 1: Percentage Of Participants With Endoscopic Improvement at Week 82.214.930.626.935.7
Statistical analysis
  • SS1: Placebo vs SS1: Upadacitinib 7.5 mg · Cochran-Mantel-Haenszel · p = 0.030 (The primary and ranked secondary efficacy endpoints were tested with multiplicity adjustment using a fixed-sequence multiple testing procedure to ensure a strong control of family-wise type I error rate at significance level alpha = 0.05 (2-sided).) · Adjusted risk difference (%): 13.1 · 95% CI 1.2 to 25.0Difference = Upadacitinib 7.5 mg - Placebo
  • SS1: Placebo vs SS1: Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.001 (The primary and ranked secondary efficacy endpoints were tested with multiplicity adjustment using a fixed-sequence multiple testing procedure to ensure a strong control of family-wise type I error rate at significance level alpha = 0.05 (2-sided).) · Adjusted risk difference (%): 27.6 · 95% CI 13.1 to 42.1Difference = Upadacitinib 15 mg - Placebo
  • SS1: Placebo vs SS1: Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = <0.001 (The primary and ranked secondary efficacy endpoints were tested with multiplicity adjustment using a fixed-sequence multiple testing procedure to ensure a strong control of family-wise type I error rate at significance level alpha = 0.05 (2-sided).) · Adjusted risk difference (%): 26.6 · 95% CI 12.3 to 40.8Difference = Upadacitinib 30 mg - Placebo
  • SS1: Placebo vs SS1: Upadacitinib 45 mg · Cochran-Mantel-Haenszel · p = <0.001 (The primary and ranked secondary efficacy endpoints were tested with multiplicity adjustment using a fixed-sequence multiple testing procedure to ensure a strong control of family-wise type I error rate at significance level alpha = 0.05 (2-sided).) · Adjusted risk difference (%): 35.4 · 95% CI 19.2 to 51.7Difference = Upadacitinib 45 mg - Placebo
SecondarySubstudy 1: Percentage Of Participants Achieving Clinical Remission Per Full Mayo Score at Week 8

The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The Full Mayo score (FMS) ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Clinical remission per FMS is defined as Mayo Score ≤ 2 and no individual subscore \> 1.

Time frame:
At Week 8
Reported as:
Number · percentage of participants
Substudy 1: Percentage Of Participants Achieving Clinical Remission Per Full Mayo Score at Week 8
percentage of participantsSS1: PlaceboSS1: Upadacitinib 7.5 mgSS1: Upadacitinib 15 mgSS1: Upadacitinib 30 mgSS1: Upadacitinib 45 mg
Substudy 1: Percentage Of Participants Achieving Clinical Remission Per Full Mayo Score at Week 8010.610.211.519.6
Statistical analysis
  • SS1: Placebo vs SS1: Upadacitinib 7.5 mg · Cochran-Mantel-Haenszel · p = 0.021 (The primary and ranked secondary efficacy endpoints were tested with multiplicity adjustment using a fixed-sequence multiple testing procedure to ensure a strong control of family-wise type I error rate at significance level alpha = 0.05 (2-sided).) · Adjusted risk difference (%): 11.0 · 95% CI 1.7 to 20.4Difference = Upadacitinib 7.5 mg - Placebo
  • SS1: Placebo vs SS1: Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = 0.024 (The primary and ranked secondary efficacy endpoints were tested with multiplicity adjustment using a fixed-sequence multiple testing procedure to ensure a strong control of family-wise type I error rate at significance level alpha = 0.05 (2-sided).) · Adjusted risk difference (%): 9.6 · 95% CI 1.3 to 18.0Difference = Upadacitinib 15 mg - Placebo
  • SS1: Placebo vs SS1: Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = 0.015 (The primary and ranked secondary efficacy endpoints were tested with multiplicity adjustment using a fixed-sequence multiple testing procedure to ensure a strong control of family-wise type I error rate at significance level alpha = 0.05 (2-sided).) · Adjusted risk difference (%): 12.2 · 95% CI 2.3 to 22.0Difference = Upadacitinib 30 mg - Placebo
  • SS1: Placebo vs SS1: Upadacitinib 45 mg · Cochran-Mantel-Haenszel · p = 0.001 (The primary and ranked secondary efficacy endpoints were tested with multiplicity adjustment using a fixed-sequence multiple testing procedure to ensure a strong control of family-wise type I error rate at significance level alpha = 0.05 (2-sided).) · Adjusted risk difference (%): 20.1 · 95% CI 8.0 to 32.1Difference = Upadacitinib 45 mg - Placebo
SecondarySubstudy 1: Percentage Of Participants Achieving Clinical Response Per Adapted Mayo Score at Week 8

The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed). 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). The overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease. Clinical response is defined as a decrease from baseline in the Adapted Mayo score ≥ 2 points and ≥ 30% from baseline, and a decrease in RBS ≥ 1 or an absolute RBS ≤ 1).

Time frame:
At Week 8
Reported as:
Number · percentage of participants
Substudy 1: Percentage Of Participants Achieving Clinical Response Per Adapted Mayo Score at Week 8
percentage of participantsSS1: PlaceboSS1: Upadacitinib 7.5 mgSS1: Upadacitinib 15 mgSS1: Upadacitinib 30 mgSS1: Upadacitinib 45 mg
Substudy 1: Percentage Of Participants Achieving Clinical Response Per Adapted Mayo Score at Week 813.029.849.046.255.4
Statistical analysis
  • SS1: Placebo vs SS1: Upadacitinib 7.5 mg · Cochran-Mantel-Haenszel · p = 0.038 (The primary and ranked secondary efficacy endpoints were tested with multiplicity adjustment using a fixed-sequence multiple testing procedure to ensure a strong control of family-wise type I error rate at significance level alpha = 0.05 (2-sided).) · Adjusted risk difference (%): 16.7 · 95% CI 0.9 to 32.5Difference = Upadacitinib 7.5 mg - Placebo
  • SS1: Placebo vs SS1: Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.001 (The primary and ranked secondary efficacy endpoints were tested with multiplicity adjustment using a fixed-sequence multiple testing procedure to ensure a strong control of family-wise type I error rate at significance level alpha = 0.05 (2-sided).) · Adjusted risk difference (%): 35.2 · 95% CI 17.5 to 52.8Difference = Upadacitinib 15 mg - Placebo
  • SS1: Placebo vs SS1: Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = <0.001 (The primary and ranked secondary efficacy endpoints were tested with multiplicity adjustment using a fixed-sequence multiple testing procedure to ensure a strong control of family-wise type I error rate at significance level alpha = 0.05 (2-sided).) · Adjusted risk difference (%): 33.6 · 95% CI 16.3 to 50.8Difference = Upadacitinib 30 mg - Placebo
  • SS1: Placebo vs SS1: Upadacitinib 45 mg · Cochran-Mantel-Haenszel · p = <0.001 (The primary and ranked secondary efficacy endpoints were tested with multiplicity adjustment using a fixed-sequence multiple testing procedure to ensure a strong control of family-wise type I error rate at significance level alpha = 0.05 (2-sided).) · Adjusted risk difference (%): 45.1 · 95% CI 26.2 to 63.9Difference = Upadacitinib 45 mg - Placebo
SecondarySubstudy 1: Percentage Of Participants Achieving Clinical Response Per Partial Mayo Score at Week 2

The Partial Mayo Score is a composite score of UC disease activity based on the following 2 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed). The overall Partial Mayo score ranges from 0 to 6 with higher scores representing more severe disease. Clinical response per Partial Mayo Score is defined as a decrease in Partial Adapted Mayo score ≥ 2 points and ≥ 30% from Baseline, plus a decrease in RBS ≥ 1 or an absolute RBS ≤ 1.

Time frame:
At Week 2
Reported as:
Number · percentage of participants
Substudy 1: Percentage Of Participants Achieving Clinical Response Per Partial Mayo Score at Week 2
percentage of participantsSS1: PlaceboSS1: Upadacitinib 7.5 mgSS1: Upadacitinib 15 mgSS1: Upadacitinib 30 mgSS1: Upadacitinib 45 mg
Substudy 1: Percentage Of Participants Achieving Clinical Response Per Partial Mayo Score at Week 217.423.434.736.555.4
Statistical analysis
  • SS1: Placebo vs SS1: Upadacitinib 7.5 mg · Cochran-Mantel-Haenszel · p = 0.495 (The primary and ranked secondary efficacy endpoints were tested with multiplicity adjustment using a fixed-sequence multiple testing procedure to ensure a strong control of family-wise type I error rate at significance level alpha = 0.05 (2-sided).) · Adjusted risk difference (%): 5.9 · 95% CI -11.1 to 22.9Difference = Upadacitinib 7.5 mg - Placebo
  • SS1: Placebo vs SS1: Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = 0.074 (The primary and ranked secondary efficacy endpoints were tested with multiplicity adjustment using a fixed-sequence multiple testing procedure to ensure a strong control of family-wise type I error rate at significance level alpha = 0.05 (2-sided).) · Adjusted risk difference (%): 15.9 · 95% CI -1.6 to 33.4Difference = Upadacitinib 15 mg - Placebo
  • SS1: Placebo vs SS1: Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = 0.033 (The primary and ranked secondary efficacy endpoints were tested with multiplicity adjustment using a fixed-sequence multiple testing procedure to ensure a strong control of family-wise type I error rate at significance level alpha = 0.05 (2-sided).) · Adjusted risk difference (%): 19.2 · 95% CI 1.6 to 36.9Difference = Upadacitinib 30 mg - Placebo
  • SS1: Placebo vs SS1: Upadacitinib 45 mg · Cochran-Mantel-Haenszel · p = <0.001 (The primary and ranked secondary efficacy endpoints were tested with multiplicity adjustment using a fixed-sequence multiple testing procedure to ensure a strong control of family-wise type I error rate at significance level alpha = 0.05 (2-sided).) · Adjusted risk difference (%): 40.1 · 95% CI 20.5 to 59.7Difference = Upadacitinib 45 mg - Placebo
SecondarySubstudy 1: Change in Full Mayo Score From Baseline to Week 8

The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The Full Mayo score (FMS) ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Clinical remission per FMS is defined as Mayo Score ≤ 2 and no individual subscore \> 1.

Time frame:
Baseline (Week 0), Week 8
Reported as:
Mean · units on a scale
Substudy 1: Change in Full Mayo Score From Baseline to Week 8
units on a scaleSS1: PlaceboSS1: Upadacitinib 7.5 mgSS1: Upadacitinib 15 mgSS1: Upadacitinib 30 mgSS1: Upadacitinib 45 mg
Substudy 1: Change in Full Mayo Score From Baseline to Week 8-0.741 ± 2.3302-2.870 ± 2.9685-3.589 ± 2.4984-4.211 ± 3.0886-4.606 ± 2.8976
Statistical analysis
  • SS1: Placebo vs SS1: Upadacitinib 7.5 mg · ANCOVA · p = <0.001 (The primary and ranked secondary efficacy endpoints were tested with multiplicity adjustment using a fixed-sequence multiple testing procedure to ensure a strong control of family-wise type I error rate at significance level alpha = 0.05 (2-sided).) · Ls mean difference: -2.142 · 95% CI -3.2323 to -1.0520Difference = Upadacitinib 7.5 mg - Placebo
  • SS1: Placebo vs SS1: Upadacitinib 15 mg · ANCOVA · p = <0.001 (The primary and ranked secondary efficacy endpoints were tested with multiplicity adjustment using a fixed-sequence multiple testing procedure to ensure a strong control of family-wise type I error rate at significance level alpha = 0.05 (2-sided).) · Ls mean difference: -2.938 · 95% CI -4.0284 to -1.8478Difference = Upadacitinib 15 mg - Placebo
  • SS1: Placebo vs SS1: Upadacitinib 30 mg · ANCOVA · p = <0.001 (The primary and ranked secondary efficacy endpoints were tested with multiplicity adjustment using a fixed-sequence multiple testing procedure to ensure a strong control of family-wise type I error rate at significance level alpha = 0.05 (2-sided).) · Ls mean difference: -3.736 · 95% CI -4.8247 to -2.6470Difference = Upadacitinib 30 mg - Placebo
  • SS1: Placebo vs SS1: Upadacitinib 45 mg · ANCOVA · p = <0.001 (The primary and ranked secondary efficacy endpoints were tested with multiplicity adjustment using a fixed-sequence multiple testing procedure to ensure a strong control of family-wise type I error rate at significance level alpha = 0.05 (2-sided).) · Ls mean difference: -4.061 · 95% CI -5.1252 to -2.9974Difference = Upadacitinib 45 mg - Placebo
SecondarySubstudy 1: Percentage Of Participants With Endoscopic Remission at Week 8

Endoscopic remission is defined as an endoscopic subscore of 0. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).

Time frame:
At Week 8
Reported as:
Number · percentage of participants
Substudy 1: Percentage Of Participants With Endoscopic Remission at Week 8
percentage of participantsSS1: PlaceboSS1: Upadacitinib 7.5 mgSS1: Upadacitinib 15 mgSS1: Upadacitinib 30 mgSS1: Upadacitinib 45 mg
Substudy 1: Percentage Of Participants With Endoscopic Remission at Week 806.44.19.617.9
Statistical analysis
  • SS1: Placebo vs SS1: Upadacitinib 7.5 mg · Cochran-Mantel-Haenszel · p = 0.075 (The primary and ranked secondary efficacy endpoints were tested with multiplicity adjustment using a fixed-sequence multiple testing procedure to ensure a strong control of family-wise type I error rate at significance level alpha = 0.05 (2-sided).) · Adjusted risk difference (%): 6.6 · 95% CI -0.7 to 13.9Difference = Upadacitinib 7.5 mg - Placebo
  • SS1: Placebo vs SS1: Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = 0.199 (The primary and ranked secondary efficacy endpoints were tested with multiplicity adjustment using a fixed-sequence multiple testing procedure to ensure a strong control of family-wise type I error rate at significance level alpha = 0.05 (2-sided).) · Adjusted risk difference (%): 3.8 · 95% CI -2.0 to 9.6Difference = Upadacitinib 15 mg - Placebo
  • SS1: Placebo vs SS1: Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = 0.015 (The primary and ranked secondary efficacy endpoints were tested with multiplicity adjustment using a fixed-sequence multiple testing procedure to ensure a strong control of family-wise type I error rate at significance level alpha = 0.05 (2-sided).) · Adjusted risk difference (%): 11.1 · 95% CI 2.2 to 20.0Difference = Upadacitinib 30 mg - Placebo
  • SS1: Placebo vs SS1: Upadacitinib 45 mg · Cochran-Mantel-Haenszel · p = 0.004 (The primary and ranked secondary efficacy endpoints were tested with multiplicity adjustment using a fixed-sequence multiple testing procedure to ensure a strong control of family-wise type I error rate at significance level alpha = 0.05 (2-sided).) · Adjusted risk difference (%): 17.8 · 95% CI 5.8 to 29.9Difference = Upadacitinib 45 mg - Placebo
SecondarySubstudy 1: Percentage Of Participants Who Achieved Histologic Improvement at Week 8

The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration. Histologic improvement was defined as decrease from baseline in Geboes score.

Time frame:
At Week 8
Reported as:
Number · percentage of participants
Substudy 1: Percentage Of Participants Who Achieved Histologic Improvement at Week 8
percentage of participantsSS1: PlaceboSS1: Upadacitinib 7.5 mgSS1: Upadacitinib 15 mgSS1: Upadacitinib 30 mgSS1: Upadacitinib 45 mg
Substudy 1: Percentage Of Participants Who Achieved Histologic Improvement at Week 86.531.951.044.248.2
Statistical analysis
  • SS1: Placebo vs SS1: Upadacitinib 7.5 mg · Cochran-Mantel-Haenszel · p = 0.003 (The primary and ranked secondary efficacy endpoints were tested with multiplicity adjustment using a fixed-sequence multiple testing procedure to ensure a strong control of family-wise type I error rate at significance level alpha = 0.05 (2-sided).) · Adjusted risk difference (%): 25.6 · 95% CI 8.9 to 42.3Difference = Upadacitinib 7.5 mg - Placebo
  • SS1: Placebo vs SS1: Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.001 (The primary and ranked secondary efficacy endpoints were tested with multiplicity adjustment using a fixed-sequence multiple testing procedure to ensure a strong control of family-wise type I error rate at significance level alpha = 0.05 (2-sided).) · Adjusted risk difference (%): 43.6 · 95% CI 25.4 to 61.8Difference = Upadacitinib 15 mg - Placebo
  • SS1: Placebo vs SS1: Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = <0.001 (The primary and ranked secondary efficacy endpoints were tested with multiplicity adjustment using a fixed-sequence multiple testing procedure to ensure a strong control of family-wise type I error rate at significance level alpha = 0.05 (2-sided).) · Adjusted risk difference (%): 39.4 · 95% CI 21.3 to 57.5Difference = Upadacitinib 30 mg - Placebo
  • SS1: Placebo vs SS1: Upadacitinib 45 mg · Cochran-Mantel-Haenszel · p = <0.001 (The primary and ranked secondary efficacy endpoints were tested with multiplicity adjustment using a fixed-sequence multiple testing procedure to ensure a strong control of family-wise type I error rate at significance level alpha = 0.05 (2-sided).) · Adjusted risk difference (%): 43.1 · 95% CI 24.4 to 61.9Difference = Upadacitinib 45 mg - Placebo
SecondarySubstudy 2: Percentage Of Participants With Endoscopic Improvement at Week 8

Endoscopic improvement is defined as an endoscopic subscore of 0 or 1. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).

Time frame:
At Week 8
Reported as:
Number · percentage of participants
Substudy 2: Percentage Of Participants With Endoscopic Improvement at Week 8
percentage of participantsSS2: PlaceboSS2: Upadacitinib 45 mg
Substudy 2: Percentage Of Participants With Endoscopic Improvement at Week 87.4 (3.2 to 11.5)36.3 (31.0 to 41.7)
Statistical analysis
  • SS2: Placebo vs SS2: Upadacitinib 45 mg · Cochran-Mantel-Haenszel · p = <0.001 (The primary and ranked secondary efficacy endpoints were tested with multiplicity adjustment using a fixed-sequence multiple testing procedure to ensure a strong control of family-wise type I error rate at significance level alpha = 0.05 (2-sided).) · Adjusted risk difference (%): 29.3 · 95% CI 22.6 to 35.9Difference = Upadacitinib 45 mg - Placebo
SecondarySubstudy 2: Percentage Of Participants With Endoscopic Remission at Week 8

Endoscopic remission is defined as an endoscopic subscore of 0. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).

Time frame:
At Week 8
Reported as:
Number · percentage of participants
Substudy 2: Percentage Of Participants With Endoscopic Remission at Week 8
percentage of participantsSS2: PlaceboSS2: Upadacitinib 45 mg
Substudy 2: Percentage Of Participants With Endoscopic Remission at Week 81.3 (0.0 to 3.1)13.7 (9.9 to 17.6)
Statistical analysis
  • SS2: Placebo vs SS2: Upadacitinib 45 mg · Cochran-Mantel-Haenszel · p = <0.001 (The primary and ranked secondary efficacy endpoints were tested with multiplicity adjustment using a fixed-sequence multiple testing procedure to ensure a strong control of family-wise type I error rate at significance level alpha = 0.05 (2-sided).) · Adjusted risk difference (%): 12.7 · 95% CI 8.4 to 17.0Difference = Upadacitinib 45 mg - Placebo
SecondarySubstudy 2: Percentage Of Participants Achieving Clinical Response Per Adapted Mayo Score at Week 8

The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed). 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). The overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease. Clinical response is defined as a decrease from baseline in the Adapted Mayo score ≥ 2 points and ≥ 30% from baseline, and a decrease in RBS ≥ 1 or an absolute RBS ≤ 1).

Time frame:
At Week 8
Reported as:
Number · percentage of participants
Substudy 2: Percentage Of Participants Achieving Clinical Response Per Adapted Mayo Score at Week 8
percentage of participantsSS2: PlaceboSS2: Upadacitinib 45 mg
Substudy 2: Percentage Of Participants Achieving Clinical Response Per Adapted Mayo Score at Week 827.3 (20.2 to 34.3)72.6 (67.7 to 77.5)
Statistical analysis
  • SS2: Placebo vs SS2: Upadacitinib 45 mg · Cochran-Mantel-Haenszel · p = <0.001 (The primary and ranked secondary efficacy endpoints were tested with multiplicity adjustment using a fixed-sequence multiple testing procedure to ensure a strong control of family-wise type I error rate at significance level alpha = 0.05 (2-sided).) · Adjusted risk difference (%): 46.3 · 95% CI 38.4 to 54.2Difference = Upadacitinib 45 mg - Placebo
SecondarySubstudy 2: Percentage Of Participants Achieving Clinical Response Per Partial Mayo Score at Week 2

The Partial Mayo Score is a composite score of UC disease activity based on the following 2 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed). The overall Partial Mayo score ranges from 0 to 6 with higher scores representing more severe disease. Clinical response per Partial Mayo Score is defined as a decrease from Baseline ≥ 1 point and ≥ 30% from Baseline, plus a decrease in RBS ≥ 1 or an absolute RBS ≤ 1.

Time frame:
At Week 2
Reported as:
Number · percentage of participants
Substudy 2: Percentage Of Participants Achieving Clinical Response Per Partial Mayo Score at Week 2
percentage of participantsSS2: PlaceboSS2: Upadacitinib 45 mg
Substudy 2: Percentage Of Participants Achieving Clinical Response Per Partial Mayo Score at Week 227.3 (20.2 to 34.3)60.1 (54.7 to 65.5)
Statistical analysis
  • SS2: Placebo vs SS2: Upadacitinib 45 mg · Cochran-Mantel-Haenszel · p = <0.001 (The primary and ranked secondary efficacy endpoints were tested with multiplicity adjustment using a fixed-sequence multiple testing procedure to ensure a strong control of family-wise type I error rate at significance level alpha = 0.05 (2-sided).) · Adjusted risk difference (%): 33.3 · 95% CI 24.8 to 41.8Stratified by bio-IR status (bio-IR vs. non-bio-IR), Baseline corticosteroid use (yes or no) and Baseline Adapted Mayo score (≤ 7 vs. \> 7)
SecondarySubstudy 2: Percentage Of Participants Who Achieved Histologic-Endoscopic Mucosal Improvement at Week 8

Histologic-endoscopic mucosal improvement is defined as an endoscopic subscore of 0 or 1 and a Geboes score ≤ 3.1. The endoscopic subscore ranges from 0 (normal or inactive disease) to 3 (severe disease with spontaneous bleeding, ulceration). The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration.

Time frame:
At Week 8
Reported as:
Number · percentage of participants
Substudy 2: Percentage Of Participants Who Achieved Histologic-Endoscopic Mucosal Improvement at Week 8
percentage of participantsSS2: PlaceboSS2: Upadacitinib 45 mg
Substudy 2: Percentage Of Participants Who Achieved Histologic-Endoscopic Mucosal Improvement at Week 86.6 (2.6 to 10.5)30.1 (25.0 to 35.1)
Statistical analysis
  • SS2: Placebo vs SS2: Upadacitinib 45 mg · Cochran-Mantel-Haenszel · p = <0.001 (The primary and ranked secondary efficacy endpoints were tested with multiplicity adjustment using a fixed-sequence multiple testing procedure to ensure a strong control of family-wise type I error rate at significance level alpha = 0.05 (2-sided).) · Adjusted risk difference (%): 23.7 · 95% CI 17.5 to 30.0Difference = Upadacitinib 45 mg - Placebo
SecondarySubstudy 2: Percentage Of Participants Who Report No Bowel Urgency at Week 8

Bowel urgency was assessed by participants in a subject diary completed once a day.

Time frame:
At Week 8
Reported as:
Number · percentage of participants
Substudy 2: Percentage Of Participants Who Report No Bowel Urgency at Week 8
percentage of participantsSS2: PlaceboSS2: Upadacitinib 45 mg
Substudy 2: Percentage Of Participants Who Report No Bowel Urgency at Week 821.4 (14.9 to 27.9)48.4 (42.9 to 53.9)
Statistical analysis
  • SS2: Placebo vs SS2: Upadacitinib 45 mg · Cochran-Mantel-Haenszel · p = <0.001 (The primary and ranked secondary efficacy endpoints were tested with multiplicity adjustment using a fixed-sequence multiple testing procedure to ensure a strong control of family-wise type I error rate at significance level alpha = 0.05 (2-sided).) · Adjusted risk difference (%): 27.4 · 95% CI 19.2 to 35.6Difference = Upadacitinib 45 mg - Placebo
SecondarySubstudy 2: Percentage Of Participants Who Reported No Abdominal Pain at Week 8

Abdominal pain was assessed by participants in a subject diary completed once a day.

Time frame:
At Week 8
Reported as:
Number · percentage of participants
Substudy 2: Percentage Of Participants Who Reported No Abdominal Pain at Week 8
percentage of participantsSS2: PlaceboSS2: Upadacitinib 45 mg
Substudy 2: Percentage Of Participants Who Reported No Abdominal Pain at Week 823.4 (16.7 to 30.1)46.6 (41.1 to 52.1)
Statistical analysis
  • SS2: Placebo vs SS2: Upadacitinib 45 mg · Cochran-Mantel-Haenszel · p = <0.001 (The primary and ranked secondary efficacy endpoints were tested with multiplicity adjustment using a fixed-sequence multiple testing procedure to ensure a strong control of family-wise type I error rate at significance level alpha = 0.05 (2-sided).) · Adjusted risk difference (%): 23.6 · 95% CI 15.1 to 32.1Difference = Upadacitinib 45 mg - Placebo
SecondarySubstudy 2: Percentage Of Participants Who Achieved Histologic Improvement at Week 8

The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration. Histologic improvement was defined as decrease from baseline in Geboes score.

Time frame:
At Week 8
Reported as:
Number · percentage of participants
Substudy 2: Percentage Of Participants Who Achieved Histologic Improvement at Week 8
percentage of participantsSS2: PlaceboSS2: Upadacitinib 45 mg
Substudy 2: Percentage Of Participants Who Achieved Histologic Improvement at Week 822.5 (15.9 to 29.1)55.0 (49.5 to 60.5)
Statistical analysis
  • SS2: Placebo vs SS2: Upadacitinib 45 mg · Cochran-Mantel-Haenszel · p = <0.001 (The primary and ranked secondary efficacy endpoints were tested with multiplicity adjustment using a fixed-sequence multiple testing procedure to ensure a strong control of family-wise type I error rate at significance level alpha = 0.05 (2-sided).) · Adjusted risk difference (%): 32.2 · 95% CI 23.8 to 40.7Difference = Upadacitinib 45 mg - Placebo
SecondarySubstudy 2: Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score at Week 8

The Inflammatory Bowel Disease Questionnaire (IBDQ) is used to assess health-related quality of life (HRQoL) in patients with ulcerative colitis. It consists of 32 questions evaluating bowel and systemic symptoms, as well as emotional and social functions. Each question is answered on a scale from 1 (worst) to 7 (best). The total score ranges from 32 to 224 with higher scores indicating better health-related quality of life. A positive change from Baseline indicates improvement.

Time frame:
Baseline (Week 0), Week 8
Reported as:
Least squares mean · units on a scale
Substudy 2: Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score at Week 8
units on a scaleSS2: PlaceboSS2: Upadacitinib 45 mg
Substudy 2: Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score at Week 821.7 (16.03 to 27.28)55.3 (51.54 to 59.15)
Statistical analysis
  • SS2: Placebo vs SS2: Upadacitinib 45 mg · Mixed-effect model repeated measurement · p = <0.001 (The primary and ranked secondary efficacy endpoints were tested with multiplicity adjustment using a fixed-sequence multiple testing procedure to ensure a strong control of family-wise type I error rate at significance level alpha = 0.05 (2-sided).) · Least squares (ls) mean difference: 33.7 · 95% CI 27.02 to 40.36Difference = Upadacitinib 45 mg - Placebo
SecondarySubstudy 2: Percentage Of Participants With Mucosal Healing at Week 8

Mucosal healing is defined as an endoscopic score of 0 and Geboes score \< 2.0. The endoscopic subscore ranges from 0 (normal or inactive disease) to 3 (severe disease with spontaneous bleeding, ulceration). The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration.

Time frame:
At Week 8
Reported as:
Number · percentage of participants
Substudy 2: Percentage Of Participants With Mucosal Healing at Week 8
percentage of participantsSS2: PlaceboSS2: Upadacitinib 45 mg
Substudy 2: Percentage Of Participants With Mucosal Healing at Week 81.3 (0.0 to 3.1)10.7 (7.3 to 14.1)
Statistical analysis
  • SS2: Placebo vs SS2: Upadacitinib 45 mg · Cochran-Mantel-Haenszel · p = <0.001 (The primary and ranked secondary efficacy endpoints were tested with multiplicity adjustment using a fixed-sequence multiple testing procedure to ensure a strong control of family-wise type I error rate at significance level alpha = 0.05 (2-sided).) · Adjusted risk difference (%): 9.7 · 95% CI 5.7 to 13.7Difference = Upadacitinib 45 mg - Placebo
SecondarySubstudy 2: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 8

The FACIT fatigue questionnaire was developed to assess fatigue associated with anemia. It consists of 13 fatigue-related questions. Each question is answered on a 5-point Likert scale: 0 (not at all); 1 (a little bit); 2 (somewhat); 3 (quite a bit); and 4 (very much). The total score ranges from 0 to 52, where higher scores represent less fatigue, and a positive change from Baseline indicates improvement.

Time frame:
Baseline (Week 0), Week 8
Reported as:
Least squares mean · units on a scale
Substudy 2: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 8
units on a scaleSS2: PlaceboSS2: Upadacitinib 45 mg
Substudy 2: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 82.8 (1.23 to 4.44)9.5 (8.44 to 10.61)
Statistical analysis
  • SS2: Placebo vs SS2: Upadacitinib 45 mg · Mixed-effect model repeated measurement · p = <0.001 (The primary and ranked secondary efficacy endpoints were tested with multiplicity adjustment using a fixed-sequence multiple testing procedure to ensure a strong control of family-wise type I error rate at significance level alpha = 0.05 (2-sided).) · Least squares (ls) mean difference: 6.7 · 95% CI 4.79 to 8.59Difference = Upadacitinib 45 mg - Placebo
SecondarySubstudy 3: Percentage Of Participants With Endoscopic Improvement at Week 52

Endoscopic improvement is defined as an endoscopic subscore of 0 or 1. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).

Time frame:
At Week 52
Reported as:
Number · percentage of participants
Substudy 3: Percentage Of Participants With Endoscopic Improvement at Week 52
percentage of participantsSS3: PlaceboSS3: UPA 15 mgSS3: UPA 30 mg
Substudy 3: Percentage Of Participants With Endoscopic Improvement at Week 5214.5 (8.7 to 20.3)48.7 (40.5 to 56.8)61.6 (53.6 to 69.6)
Statistical analysis
  • SS3: Placebo vs SS3: UPA 15 mg · Cochran-Mantel-Haenszel · p = <0.001 (The primary and ranked secondary efficacy endpoints were tested with graphical multiplicity adjustment to ensure a strong control of family-wise type I error rate at significance level α= 0.05 (2-sided).) · Adjusted risk difference (%): 34.4 · 95% CI 25.1 to 43.7Difference = Upadacitinib 15 mg - Placebo
  • SS3: Placebo vs SS3: UPA 30 mg · Cochran-Mantel-Haenszel · p = <0.001 (The primary and ranked secondary efficacy endpoints were tested with graphical multiplicity adjustment to ensure a strong control of family-wise type I error rate at significance level α= 0.05 (2-sided).) · Adjusted risk difference (%): 46.3 · 95% CI 36.7 to 55.8Difference = Upadacitinib 30 mg - Placebo
SecondarySubstudy 3: Percentage of Participants With Clinical Remission Per Adapted Mayo Score at Week 52 Among Those Who Achieved Clinical Remission at the End of the Induction Treatment

The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed). 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). The overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease. For Substudy 3, clinical remission is defined as SFS ≤ 1 and not greater than Baseline, RBS of 0, and endoscopic subscore ≤ 1. In addition, evidence of friability during endoscopy in participants with otherwise "mild" endoscopic activity conferred an endoscopic subscore of 2.

Time frame:
At Week 52
Reported as:
Number · percentage of participants
Substudy 3: Percentage of Participants With Clinical Remission Per Adapted Mayo Score at Week 52 Among Those Who Achieved Clinical Remission at the End of the Induction Treatment
percentage of participantsSS3: PlaceboSS3: UPA 15 mgSS3: UPA 30 mg
Substudy 3: Percentage of Participants With Clinical Remission Per Adapted Mayo Score at Week 52 Among Those Who Achieved Clinical Remission at the End of the Induction Treatment22.2 (11.1 to 33.3)59.2 (45.1 to 73.4)69.7 (57.7 to 81.8)
Statistical analysis
  • SS3: Placebo vs SS3: UPA 15 mg · Cochran-Mantel-Haenszel · p = <0.001 (The primary and ranked secondary efficacy endpoints were tested with graphical multiplicity adjustment to ensure a strong control of family-wise type I error rate at significance level α= 0.05 (2-sided).) · Adjusted risk difference (%): 37.4 · 95% CI 20.3 to 54.6Difference = Upadacitinib 15 mg - Placebo
  • SS3: Placebo vs SS3: UPA 30 mg · Cochran-Mantel-Haenszel · p = <0.001 (The primary and ranked secondary efficacy endpoints were tested with graphical multiplicity adjustment to ensure a strong control of family-wise type I error rate at significance level α= 0.05 (2-sided).) · Adjusted risk difference (%): 47.0 · 95% CI 30.7 to 63.3Difference = Upadacitinib 30 mg - Placebo
SecondarySubstudy 3: Percentage of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Wk 52 and Were Corticosteroid Free for ≥ 90 Days Immediately Preceding Wk 52 Among Those Who Achieved Clinical Remission at the End of the Induction Treatment

The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed). 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). The overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease. For Substudy 3, clinical remission is defined as SFS ≤ 1 and not greater than Baseline, RBS of 0, and endoscopic subscore ≤ 1. In addition, evidence of friability during endoscopy in participants with otherwise "mild" endoscopic activity conferred an endoscopic subscore of 2.

Time frame:
At Week 52
Reported as:
Number · percentage of participants
Substudy 3: Percentage of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Wk 52 and Were Corticosteroid Free for ≥ 90 Days Immediately Preceding Wk 52 Among Those Who Achieved Clinical Remission at the End of the Induction Treatment
percentage of participantsSS3: PlaceboSS3: UPA 15 mgSS3: UPA 30 mg
Substudy 3: Percentage of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Wk 52 and Were Corticosteroid Free for ≥ 90 Days Immediately Preceding Wk 52 Among Those Who Achieved Clinical Remission at the End of the Induction Treatment22.2 (11.1 to 33.3)57.1 (42.9 to 71.3)68.0 (55.8 to 80.2)
Statistical analysis
  • SS3: Placebo vs SS3: UPA 15 mg · Cochran-Mantel-Haenszel · p = <0.001 (The primary and ranked secondary efficacy endpoints were tested with graphical multiplicity adjustment to ensure a strong control of family-wise type I error rate at significance level α= 0.05 (2-sided).) · Adjusted risk difference (%): 35.4 · 95% CI 18.2 to 52.7Difference = Upadacitinib 15 mg - Placebo
  • SS3: Placebo vs SS3: UPA 30 mg · Cochran-Mantel-Haenszel · p = <0.001 (The primary and ranked secondary efficacy endpoints were tested with graphical multiplicity adjustment to ensure a strong control of family-wise type I error rate at significance level α= 0.05 (2-sided).) · Adjusted risk difference (%): 45.1 · 95% CI 28.7 to 61.6Difference = Upadacitinib 30 mg - Placebo
SecondarySubstudy 3: Percentage of Participants With Endoscopic Improvement at Wk 52 Among Those Who Achieved Endoscopic Improvement at the End of the Induction Treatment

Endoscopic improvement is defined as an endoscopic subscore of 0 or 1. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).

Time frame:
At Week 52
Reported as:
Number · percentage of participants
Substudy 3: Percentage of Participants With Endoscopic Improvement at Wk 52 Among Those Who Achieved Endoscopic Improvement at the End of the Induction Treatment
percentage of participantsSS3: PlaceboSS3: UPA 15 mgSS3: UPA 30 mg
Substudy 3: Percentage of Participants With Endoscopic Improvement at Wk 52 Among Those Who Achieved Endoscopic Improvement at the End of the Induction Treatment19.2 (9.9 to 28.4)61.6 (49.6 to 73.7)69.5 (59.1 to 80.0)
Statistical analysis
  • SS3: Placebo vs SS3: UPA 15 mg · Cochran-Mantel-Haenszel · p = <0.001 (The primary and ranked secondary efficacy endpoints were tested with graphical multiplicity adjustment to ensure a strong control of family-wise type I error rate at significance level α= 0.05 (2-sided).) · Adjusted risk difference (%): 42.0 · 95% CI 27.8 to 56.2Difference = Upadacitinib 15 mg - Placebo
  • SS3: Placebo vs SS3: UPA 30 mg · Cochran-Mantel-Haenszel · p = <0.001 (The primary and ranked secondary efficacy endpoints were tested with graphical multiplicity adjustment to ensure a strong control of family-wise type I error rate at significance level α= 0.05 (2-sided).) · Adjusted risk difference (%): 48.6 · 95% CI 35.5 to 61.7Difference = Upadacitinib 30 mg - Placebo
SecondarySubstudy 3: Percentage Of Participants With Endoscopic Remission At Week 52

Endoscopic remission is defined as an endoscopic subscore of 0. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).

Time frame:
At Week 52
Reported as:
Number · percentage of participants
Substudy 3: Percentage Of Participants With Endoscopic Remission At Week 52
percentage of participantsSS3: PlaceboSS3: UPA 15 mgSS3: UPA 30 mg
Substudy 3: Percentage Of Participants With Endoscopic Remission At Week 525.6 (1.8 to 9.3)24.2 (17.3 to 31.2)25.9 (18.8 to 33.0)
Statistical analysis
  • SS3: Placebo vs SS3: UPA 15 mg · Cochran-Mantel-Haenszel · p = <0.001 (The primary and ranked secondary efficacy endpoints were tested with graphical multiplicity adjustment to ensure a strong control of family-wise type I error rate at significance level α= 0.05 (2-sided).) · Adjusted risk difference (%): 18.7 · 95% CI 11.0 to 26.4Difference = Upadacitinib 15 mg - Placebo
  • SS3: Placebo vs SS3: UPA 30 mg · Cochran-Mantel-Haenszel · p = <0.001 (The primary and ranked secondary efficacy endpoints were tested with graphical multiplicity adjustment to ensure a strong control of family-wise type I error rate at significance level α= 0.05 (2-sided).) · Adjusted risk difference (%): 19.4 · 95% CI 11.7 to 27.2Difference = Upadacitinib 30 mg - Placebo
SecondarySubstudy 3: Percentage Of Participants Who Maintained Clinical Response Per Adapted Mayo Score at Wk 52 Among Those Who Achieved Clinical Response at the End of the Induction Treatment

The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed). 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). The overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease. Clinical response is defined as a decrease from baseline in the Adapted Mayo score ≥ 2 points and ≥ 30% from baseline, and a decrease in RBS ≥ 1 or an absolute RBS ≤ 1).

Time frame:
At Week 52
Reported as:
Number · percentage of participants
Substudy 3: Percentage Of Participants Who Maintained Clinical Response Per Adapted Mayo Score at Wk 52 Among Those Who Achieved Clinical Response at the End of the Induction Treatment
percentage of participantsSS3: PlaceboSS3: UPA 15 mgSS3: UPA 30 mg
Substudy 3: Percentage Of Participants Who Maintained Clinical Response Per Adapted Mayo Score at Wk 52 Among Those Who Achieved Clinical Response at the End of the Induction Treatment18.8 (12.1 to 25.5)63.0 (54.8 to 71.1)76.6 (69.6 to 83.6)
Statistical analysis
  • SS3: Placebo vs SS3: UPA 15 mg · Cochran-Mantel-Haenszel · p = <0.001 (The primary and ranked secondary efficacy endpoints were tested with graphical multiplicity adjustment to ensure a strong control of family-wise type I error rate at significance level α= 0.05 (2-sided).) · Adjusted risk difference (%): 44.6 · 95% CI 34.5 to 54.7Difference = Upadacitinib 15 mg - Placebo
  • SS3: Placebo vs SS3: UPA 30 mg · Cochran-Mantel-Haenszel · p = <0.001 (The primary and ranked secondary efficacy endpoints were tested with graphical multiplicity adjustment to ensure a strong control of family-wise type I error rate at significance level α= 0.05 (2-sided).) · Adjusted risk difference (%): 56.6 · 95% CI 47.2 to 66.0Difference = Upadacitinib 30 mg - Placebo
SecondarySubstudy 3: Percentage Of Participants Who Achieved Histologic-Endoscopic Mucosal Improvement at Week 52

Histologic-endoscopic mucosal improvement is defined as an endoscopic subscore of 0 or 1 and a Geboes score ≤ 3.1. The endoscopic subscore ranges from 0 (normal or inactive disease) to 3 (severe disease with spontaneous bleeding, ulceration). The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration.

Time frame:
At Week 52
Reported as:
Number · percentage of participants
Substudy 3: Percentage Of Participants Who Achieved Histologic-Endoscopic Mucosal Improvement at Week 52
percentage of participantsSS3: PlaceboSS3: UPA 15 mgSS3: UPA 30 mg
Substudy 3: Percentage Of Participants Who Achieved Histologic-Endoscopic Mucosal Improvement at Week 5211.9 (6.7 to 17.2)35.0 (27.1 to 42.8)49.8 (41.5 to 58.0)
Statistical analysis
  • SS3: Placebo vs SS3: UPA 15 mg · Cochran-Mantel-Haenszel · p = <0.001 (The primary and ranked secondary efficacy endpoints were tested with graphical multiplicity adjustment to ensure a strong control of family-wise type I error rate at significance level α= 0.05 (2-sided).) · Adjusted risk difference (%): 23.8 · 95% CI 14.8 to 32.8Difference = Upadacitinib 15 mg - Placebo
  • SS3: Placebo vs SS3: UPA 30 mg · Cochran-Mantel-Haenszel · p = <0.001 (The primary and ranked secondary efficacy endpoints were tested with graphical multiplicity adjustment to ensure a strong control of family-wise type I error rate at significance level α= 0.05 (2-sided).) · Adjusted risk difference (%): 37.3 · 95% CI 27.8 to 46.8Difference = Upadacitinib 30 mg - Placebo
SecondarySubstudy 3: Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score at Week 52

The Inflammatory Bowel Disease Questionnaire (IBDQ) is used to assess health-related quality of life (HRQoL) in patients with ulcerative colitis. It consists of 32 questions evaluating bowel and systemic symptoms, as well as emotional and social functions. Each question is answered on a scale from 1 (worst) to 7 (best). The total score ranges from 32 to 224 with higher scores indicating better health-related quality of life. A positive change from Baseline indicates improvement.

Time frame:
Baseline (Week 0), Week 52
Reported as:
Least squares mean · units on a scale
Substudy 3: Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score at Week 52
units on a scaleSS3: PlaceboSS3: UPA 15 mgSS3: UPA 30 mg
Substudy 3: Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score at Week 5217.9 (10.79 to 25.00)49.2 (42.59 to 55.89)58.9 (52.14 to 65.59)
Statistical analysis
  • SS3: Placebo vs SS3: UPA 15 mg · ANCOVA · p = <0.001 (The primary and ranked secondary efficacy endpoints were tested with graphical multiplicity adjustment to ensure a strong control of family-wise type I error rate at significance level α= 0.05 (2-sided).) · Ls mean difference: 31.3 · 95% CI 21.98 to 40.70Difference = Upadacitinib 15 mg - Placebo
  • SS3: Placebo vs SS3: UPA 30 mg · ANCOVA · p = <0.001 (The primary and ranked secondary efficacy endpoints were tested with graphical multiplicity adjustment to ensure a strong control of family-wise type I error rate at significance level α= 0.05 (2-sided).) · Ls mean difference: 41.0 · 95% CI 31.39 to 50.55Difference = Upadacitinib 30 mg - Placebo
SecondarySubstudy 3: Percentage Of Participants With Mucosal Healing at Week 52

Mucosal healing is defined as an endoscopic score of 0 and Geboes score \< 2.0. The endoscopic subscore ranges from 0 (normal or inactive disease) to 3 (severe disease with spontaneous bleeding, ulceration). The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration.

Time frame:
At Week 52
Reported as:
Number · percentage of participants
Substudy 3: Percentage Of Participants With Mucosal Healing at Week 52
percentage of participantsSS3: PlaceboSS3: UPA 15 mgSS3: UPA 30 mg
Substudy 3: Percentage Of Participants With Mucosal Healing at Week 524.7 (1.3 to 8.2)17.6 (11.4 to 23.8)19.0 (12.6 to 25.4)
Statistical analysis
  • SS3: Placebo vs SS3: UPA 15 mg · Cochran-Mantel-Haenszel · p = <0.001 (The primary and ranked secondary efficacy endpoints were tested with graphical multiplicity adjustment to ensure a strong control of family-wise type I error rate at significance level α= 0.05 (2-sided).) · Adjusted risk difference (%): 13.0 · 95% CI 6.0 to 20.0Difference = Upadacitinib 15 mg - Placebo
  • SS3: Placebo vs SS3: UPA 30 mg · Cochran-Mantel-Haenszel · p = <0.001 (The primary and ranked secondary efficacy endpoints were tested with graphical multiplicity adjustment to ensure a strong control of family-wise type I error rate at significance level α= 0.05 (2-sided).) · Adjusted risk difference (%): 13.6 · 95% CI 6.6 to 20.6Difference = Upadacitinib 30 mg - Placebo
SecondarySubstudy 3: Percentage Of Participants Who Reported No Bowel Urgency at Week 52

Bowel urgency was assessed by participants in a subject diary completed once a day.

Time frame:
At Week 52
Reported as:
Number · percentage of participants
Substudy 3: Percentage Of Participants Who Reported No Bowel Urgency at Week 52
percentage of participantsSS3: PlaceboSS3: UPA 15 mgSS3: UPA 30 mg
Substudy 3: Percentage Of Participants Who Reported No Bowel Urgency at Week 5217.4 (11.4 to 23.5)56.1 (48.1 to 64.1)63.6 (56.0 to 71.2)
Statistical analysis
  • SS3: Placebo vs SS3: UPA 15 mg · Cochran-Mantel-Haenszel · p = <0.001 (The primary and ranked secondary efficacy endpoints were tested with graphical multiplicity adjustment to ensure a strong control of family-wise type I error rate at significance level α= 0.05 (2-sided).) · Adjusted risk difference (%): 38.7 · 95% CI 28.9 to 48.5Difference = Upadacitinib 15 mg - Placebo
  • SS3: Placebo vs SS3: UPA 30 mg · Cochran-Mantel-Haenszel · p = <0.001 (The primary and ranked secondary efficacy endpoints were tested with graphical multiplicity adjustment to ensure a strong control of family-wise type I error rate at significance level α= 0.05 (2-sided).) · Adjusted risk difference (%): 45.1 · 95% CI 35.5 to 54.8Difference = Upadacitinib 30 mg - Placebo
SecondarySubstudy 3: Percentage Of Participants Who Reported No Abdominal Pain at Week 52

Abdominal pain was assessed by participants in a subject diary completed once a day.

Time frame:
At Week 52
Reported as:
Number · percentage of participants
Substudy 3: Percentage Of Participants Who Reported No Abdominal Pain at Week 52
percentage of participantsSS3: PlaceboSS3: UPA 15 mgSS3: UPA 30 mg
Substudy 3: Percentage Of Participants Who Reported No Abdominal Pain at Week 5220.8 (14.2 to 27.3)45.9 (37.9 to 54.0)55.3 (47.4 to 63.2)
Statistical analysis
  • SS3: Placebo vs SS3: UPA 15 mg · Cochran-Mantel-Haenszel · p = <0.001 (The primary and ranked secondary efficacy endpoints were tested with graphical multiplicity adjustment to ensure a strong control of family-wise type I error rate at significance level α= 0.05 (2-sided).) · Adjusted risk difference (%): 24.3 · 95% CI 14.2 to 34.5Difference = Upadacitinib 15 mg - Placebo
  • SS3: Placebo vs SS3: UPA 30 mg · Cochran-Mantel-Haenszel · p = <0.001 (The primary and ranked secondary efficacy endpoints were tested with graphical multiplicity adjustment to ensure a strong control of family-wise type I error rate at significance level α= 0.05 (2-sided).) · Adjusted risk difference (%): 33.7 · 95% CI 23.6 to 43.9Difference = Upadacitinib 30 mg - Placebo
SecondarySubstudy 3: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 52

The FACIT fatigue questionnaire was developed to assess fatigue associated with anemia. It consists of 13 fatigue-related questions. Each question is answered on a 5-point Likert scale: 0 (not at all); 1 (a little bit); 2 (somewhat); 3 (quite a bit); and 4 (very much). The total score ranges from 0 to 52, where higher scores represent less fatigue, and a positive change from Baseline indicates improvement.

Time frame:
Baseline (Week 0), Week 52
Reported as:
Least squares mean · units on a scale
Substudy 3: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 52
units on a scaleSS3: PlaceboSS3: UPA 15 mgSS3: UPA 30 mg
Substudy 3: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 523.7 (1.88 to 5.43)8.7 (7.01 to 10.49)9.5 (7.80 to 11.22)
Statistical analysis
  • SS3: Placebo vs SS3: UPA 15 mg · ANCOVA · p = <0.001 (The primary and ranked secondary efficacy endpoints were tested with graphical multiplicity adjustment to ensure a strong control of family-wise type I error rate at significance level α= 0.05 (2-sided).) · Ls mean difference: 5.1 · 95% CI 2.67 to 7.52Difference = Upadacitinib 15 mg - Placebo
  • SS3: Placebo vs SS3: UPA 30 mg · ANCOVA · p = <0.001 (The primary and ranked secondary efficacy endpoints were tested with graphical multiplicity adjustment to ensure a strong control of family-wise type I error rate at significance level α= 0.05 (2-sided).) · Ls mean difference: 5.9 · 95% CI 3.44 to 8.27Difference = Upadacitinib 30 mg - Placebo

Adverse events

Collected over All-cause mortality is reported from enrollment to end of study; median time on follow-up was up to 57, 61, and 364 days for Substudies 1, 2, and 3, respectively. TEAEs and SAEs were collected from first dose of study drug until 30 days after last dose of study drug; mean duration on study drug was up to 57, 56, and 364 days for Substudies 1, 2, and 3, respectively.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SS1: Placebo0/46 (0%)5/46 (10.9%)27/46 (58.7%)
SS1: Upadacitinib 7.5 mg0/47 (0%)0/47 (0%)18/47 (38.3%)
SS1: Upadacitinib 15 mg0/49 (0%)2/49 (4.1%)22/49 (44.9%)
SS1: Upadacitinib 30 mg0/117 (0%)5/117 (4.3%)58/117 (49.6%)
SS1: Upadacitinib 45 mg0/123 (0%)6/123 (4.9%)50/123 (40.7%)
SS2: Placebo0/155 (0%)9/155 (5.8%)62/155 (40%)
SS2: Upadacitinib 45 mg0/319 (0%)8/319 (2.5%)121/319 (37.9%)
SS2: Placebo/Upadacitinib 45 mg0/85 (0%)2/85 (2.4%)36/85 (42.4%)
SS2: Upadacitinib 45 mg/Upadacitinib 45 mg0/59 (0%)2/59 (3.4%)17/59 (28.8%)
SS3: Placebo0/385 (0%)32/385 (8.3%)216/385 (56.1%)
SS3: Upadacitinib 7.5 mg0/20 (0%)0/20 (0%)18/20 (90%)
SS3: Upadacitinib 15 mg0/323 (0%)24/323 (7.4%)181/323 (56%)
SS3: Upadacitinib 30 mg0/316 (0%)25/316 (7.9%)166/316 (52.5%)
Most frequent serious events
Showing 10 of 85
Most frequent serious events
EventSS1: PlaceboSS1: Upadacitinib 7.5 mgSS1: Upadacitinib 15 mgSS1: Upadacitinib 30 mgSS1: Upadacitinib 45 mgSS2: PlaceboSS2: Upadacitinib 45 mgSS2: Placebo/Upadacitinib 45 mgSS2: Upadacitinib 45 mg/Upadacitinib 45 mgSS3: PlaceboSS3: Upadacitinib 7.5 mgSS3: Upadacitinib 15 mgSS3: Upadacitinib 30 mg
COLITIS ULCERATIVEGastrointestinal disorders2/460/471/494/1173/1235/1552/3191/851/599/3850/201/3233/316
ANAEMIABlood and lymphatic system disorders0/460/470/490/1170/1230/1550/3192/850/590/3850/200/3231/316
CELLULITISInfections and infestations1/460/470/490/1170/1231/1550/3190/850/591/3850/200/3230/316
SINUSITISInfections and infestations1/460/470/490/1170/1230/1550/3190/850/590/3850/200/3230/316
HYPOPHOSPHATAEMIAMetabolism and nutrition disorders1/460/470/490/1170/1230/1550/3190/850/590/3850/200/3230/316
UROSEPSISInfections and infestations0/460/471/490/1170/1230/1550/3190/850/590/3850/200/3230/316
HYPOTENSIONVascular disorders0/460/470/490/1170/1230/1550/3190/851/590/3850/200/3230/316
ILEUSGastrointestinal disorders0/460/470/491/1170/1230/1550/3190/850/590/3850/200/3230/316
CYSTITIS HAEMORRHAGICRenal and urinary disorders0/460/470/491/1170/1230/1550/3190/850/590/3850/200/3230/316
ABDOMINAL PAINGastrointestinal disorders0/460/470/490/1171/1230/1550/3190/850/590/3850/200/3230/316
Most frequent other events
Showing 10 of 63
Most frequent other events
EventSS1: PlaceboSS1: Upadacitinib 7.5 mgSS1: Upadacitinib 15 mgSS1: Upadacitinib 30 mgSS1: Upadacitinib 45 mgSS2: PlaceboSS2: Upadacitinib 45 mgSS2: Placebo/Upadacitinib 45 mgSS2: Upadacitinib 45 mg/Upadacitinib 45 mgSS3: PlaceboSS3: Upadacitinib 7.5 mgSS3: Upadacitinib 15 mgSS3: Upadacitinib 30 mg
COLITIS ULCERATIVEGastrointestinal disorders4/461/472/494/1173/12316/1551/3192/851/59101/3853/2040/32324/316
ARTHRALGIAMusculoskeletal and connective tissue disorders1/462/470/492/1173/1237/1555/3190/850/5928/3854/2019/3238/316
HEADACHENervous system disorders5/464/474/499/1178/1234/15513/3194/852/5916/3850/2010/32314/316
CONSTIPATIONGastrointestinal disorders1/460/470/491/1171/1230/1556/3192/850/592/3852/204/3237/316
DIARRHOEAGastrointestinal disorders0/460/470/490/1172/1230/1551/3190/850/594/3852/202/3232/316
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations0/461/474/493/1176/1236/1558/3190/850/5911/3852/2019/32315/316
URINARY TRACT INFECTIONInfections and infestations0/461/470/493/1171/1233/1553/3192/850/599/3852/2010/3234/316
COUGHRespiratory, thoracic and mediastinal disorders1/461/471/493/1174/1232/1555/3192/851/596/3852/206/3234/316
RASHSkin and subcutaneous tissue disorders0/461/470/495/1171/1231/1558/3190/851/5914/3852/209/32314/316
NASOPHARYNGITISInfections and infestations3/461/473/493/1174/1236/15515/3194/851/5927/3850/2031/32330/316

Baseline characteristics

Intent-to-treat (ITT) analysis set: Substudy 1 (all randomized participants who received at least one dose of study drug in Substudy 1); Substudy 2 (all randomized participants who received at least one dose of doubleblinded study drug in Part 1 and all participants who received at least one dose of upadacitinib 45 mg in Part 2); Substudy 3 (all M14-675 participants who received at least one dose of study drug in Substudy 3)

Age, Continuous
Age, Continuous(years)SS1: PlaceboSS1: Upadacitinib 7.5 mgSS1: Upadacitinib 15 mgSS1: Upadacitinib 30 mgSS1: Upadacitinib 45 mgSS2: Placebo/Upadacitinib 45 mgSS2: Upadacitinib 45 mg/Upadacitinib 45 mgSS3: M14-675 Clinical RespondersTotal
Mean42.3 ± 13.2941.7 ± 14.5846.0 ± 13.5842.9 ± 14.4441.6 ± 14.1944.3 ± 14.6443.6 ± 14.0442.1 ± 14.4242.9 ± 14.27
Sex: Female, Male
Sex: Female, Male(Participants)SS1: PlaceboSS1: Upadacitinib 7.5 mgSS1: Upadacitinib 15 mgSS1: Upadacitinib 30 mgSS1: Upadacitinib 45 mgSS2: Placebo/Upadacitinib 45 mgSS2: Upadacitinib 45 mg/Upadacitinib 45 mgSS3: M14-675 Clinical RespondersTotal
Female172419474458121170500
Male292330707997198276802
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)SS1: PlaceboSS1: Upadacitinib 7.5 mgSS1: Upadacitinib 15 mgSS1: Upadacitinib 30 mgSS1: Upadacitinib 45 mgSS2: Placebo/Upadacitinib 45 mgSS2: Upadacitinib 45 mg/Upadacitinib 45 mgSS3: M14-675 Clinical RespondersTotal
White3736388890101206302898
Black or African American031324121540
Asian871023284695124341
American Indian or Alaska Native000102014
Native Hawaiian or Other Pacific Islander000000112
Multiple1102325317
Average Stool Frequency Subscore
Average Stool Frequency Subscore(units on a scale)SS1: PlaceboSS1: Upadacitinib 7.5 mgSS1: Upadacitinib 15 mgSS1: Upadacitinib 30 mgSS1: Upadacitinib 45 mgSS2: Placebo/Upadacitinib 45 mgSS2: Upadacitinib 45 mg/Upadacitinib 45 mgSS3: M14-675 Clinical RespondersTotal
Mean2.56 ± 0.6672.62 ± 0.6002.68 ± 0.5652.61 ± 0.6132.58 ± 0.6482.52 ± 0.6682.60 ± 0.6242.55 ± 0.6232.58 ± 0.628
Average Rectal Bleeding Subscore
Average Rectal Bleeding Subscore(units on a scale)SS1: PlaceboSS1: Upadacitinib 7.5 mgSS1: Upadacitinib 15 mgSS1: Upadacitinib 30 mgSS1: Upadacitinib 45 mgSS2: Placebo/Upadacitinib 45 mgSS2: Upadacitinib 45 mg/Upadacitinib 45 mgSS3: M14-675 Clinical RespondersTotal
Mean1.66 ± 1.0341.61 ± 1.0271.55 ± 0.9151.51 ± 0.9751.49 ± 0.9601.76 ± 0.9941.71 ± 1.0461.77 ± 0.9901.68 ± 1.003
Average Endoscopy Subscore
Average Endoscopy Subscore(units on a scale)SS1: PlaceboSS1: Upadacitinib 7.5 mgSS1: Upadacitinib 15 mgSS1: Upadacitinib 30 mgSS1: Upadacitinib 45 mgSS2: Placebo/Upadacitinib 45 mgSS2: Upadacitinib 45 mg/Upadacitinib 45 mgSS3: M14-675 Clinical RespondersTotal
Mean2.8 ± 0.432.8 ± 0.402.8 ± 0.392.7 ± 0.472.7 ± 0.482.7 ± 0.472.7 ± 0.462.7 ± 0.472.7 ± 0.46
Previous Biologic Use
Previous Biologic Use(Participants)SS1: PlaceboSS1: Upadacitinib 7.5 mgSS1: Upadacitinib 15 mgSS1: Upadacitinib 30 mgSS1: Upadacitinib 45 mgSS2: Placebo/Upadacitinib 45 mgSS2: Upadacitinib 45 mg/Upadacitinib 45 mgSS3: M14-675 Clinical RespondersTotal
Yes3536388792———288
No1111113031———94
Biologic-inadequate Responder (Bio-IR) Status
Biologic-inadequate Responder (Bio-IR) Status(Participants)SS1: PlaceboSS1: Upadacitinib 7.5 mgSS1: Upadacitinib 15 mgSS1: Upadacitinib 30 mgSS1: Upadacitinib 45 mgSS2: Placebo/Upadacitinib 45 mgSS2: Upadacitinib 45 mg/Upadacitinib 45 mgSS3: M14-675 Clinical RespondersTotal
Bio-IR—————79168221468
Non-Bio-IR—————76151225452

1 further baseline measures are reported on the registry.

08

Study locations

496 sites
  • Birmingham Gastroenterology Associates P.C /ID# 151276
    Birmingham, Alabama 35209, United States
  • East View Medical Research, LLC /ID# 171183
    Mobile, Alabama 36606, United States
  • CB Flock Research Corporation /ID# 165980
    Mobile, Alabama 36608, United States
  • Delsol Research Management, Ll /Id# 170131
    Chandler, Arizona 85224, United States
  • Digestive Disease Consultants, A Division of Arizona Digestive Health, P.C /ID# 211885
    Mesa, Arizona 85206, United States
  • Arizona Arthritis & Rheumatology Research, PLLC /ID# 169822
    Sun City, Arizona 85306, United States
  • Adobe Clinical Research LLC /ID# 155250
    Tucson, Arizona 85712, United States
  • University of Arizona /ID# 150553
    Tucson, Arizona 85724, United States
  • Citrus Valley Gastroenterology /ID# 151914
    Covina, California 91722-3797, United States
  • Newport Huntington Medical Group /ID# 217005
    Huntington Beach, California 92648-5994, United States
  • UC San Diego Health System /ID# 155185
    La Jolla, California 92093, United States
  • United Medical Doctors /ID# 207464
    Los Alamitos, California 90720-3309, United States
  • TLC Clinical Research Inc /ID# 216829
    Los Angeles, California 90048, United States
  • Gastrointestinal Biosciences Clinical Trials, LLC /ID# 157080
    Los Angeles, California 90067-2001, United States
  • Facey Medical Foundation /ID# 203133
    Mission Hills, California 91345, United States
  • United Medical Doctors - Murrieta /ID# 151211
    Murrieta, California 92563, United States
  • InSite Digestive Health Care - Oxnard /ID# 163414
    Oxnard, California 93030, United States
  • Inland Empire Clinical Trials, LLC /ID# 216038
    Rialto, California 92377, United States
  • San Diego Clinical Trials /ID# 212120
    San Diego, California 92120, United States
  • Medical Assoc Research Grp /ID# 169148
    San Diego, California 92123, United States
  • Univ of California San Francis /ID# 164581
    San Francisco, California 94158, United States
  • Delta Waves, Inc. /ID# 151721
    Colorado Springs, Colorado 80918, United States
  • South Denver Gastroenterology /ID# 151223
    Lone Tree, Colorado 80124, United States
  • Western States Clinical Res /ID# 158076
    Wheat Ridge, Colorado 80033-2896, United States
  • Western Connecticut Medical Group /ID# 169210
    Danbury, Connecticut 06810, United States
  • Medical Research Center of CT /ID# 150482
    Hamden, Connecticut 06518, United States
  • Gastro Florida /ID# 155245
    Clearwater, Florida 33756, United States
  • Moonshine Research Center, Inc /ID# 152533
    Doral, Florida 33166, United States
  • Universal Axon Clinical Research /ID# 213461
    Doral, Florida 33166, United States
  • Palmetto Research, LLC /ID# 151716
    Hialeah, Florida 33016, United States
  • Nature Coast Clinical Research - Inverness /ID# 154064
    Inverness, Florida 34452-4717, United States
  • Encore Borland-Groover Clinical Research /Id# 170912
    Jacksonville, Florida 32256, United States
  • SIH Research Mumtaz, Inc /ID# 163319
    Kissimmee, Florida 34741-4161, United States
  • Cfagi Llc /Id# 202017
    Maitland, Florida 32751-6108, United States
  • University of Miami /ID# 215441
    Miami, Florida 33136, United States
  • Advanced Pharma /ID# 151719
    Miami, Florida 33147, United States
  • New Horizon Research Center /ID# 152474
    Miami, Florida 33165-3372, United States
  • Crystal Pharmacology Research /ID# 151841
    Miami, Florida 33165, United States
  • Coral Research Clinic /ID# 150444
    Miami, Florida 33186-4643, United States
  • Advanced Research Institute, Inc /ID# 163098
    New Port Richey, Florida 34653, United States
  • Endoscopic Research, Inc. /ID# 151720
    Orlando, Florida 32803, United States
  • Omega Research Maitland, LLC /ID# 200269
    Orlando, Florida 32808, United States
  • Clinical Research Trials of Florida, Inc. /ID# 201790
    Tampa, Florida 33607, United States
  • University of South Florida /ID# 214493
    Tampa, Florida 33612, United States
  • AdventHealth Tampa /ID# 200272
    Tampa, Florida 33613-4680, United States
  • Gastroenterology Associates of Central Georgia, LLC /ID# 165782
    Macon, Georgia 31201, United States
  • Infinite Clinical Trials /ID# 215340
    Riverdale, Georgia 30274, United States
  • Atlanta Gastroenterology Spec /ID# 150548
    Suwanee, Georgia 30024, United States
  • Next Innovative Clinical Research - Chicago /ID# 216060
    Chicago, Illinois 60605-2168, United States
  • The University of Chicago DCAM /ID# 150547
    Chicago, Illinois 60637, United States
  • NorthShore University HealthSystem /ID# 150555
    Evanston, Illinois 60201, United States
  • Northwest Health Care Associates /ID# 151590
    Hoffman Estates, Illinois 60169, United States
  • Carle Foundation Hospital /ID# 151137
    Urbana, Illinois 61801, United States
  • MediSphere Medical Research Center /ID# 152064
    Evansville, Indiana 47714-8011, United States
  • Indianapolis Gastroenterology /ID# 162901
    Indianapolis, Indiana 46237, United States
  • University of Iowa Hospitals and Clinics /ID# 157058
    Iowa City, Iowa 52242, United States
  • Cotton-O'Neil Clinical Res Ctr /ID# 167182
    Topeka, Kansas 66606, United States
  • Tri-State Gastroenterology /ID# 169811
    Crestview Hills, Kentucky 41017, United States
  • Houma Digestive Health Special /ID# 151844
    Houma, Louisiana 70360, United States
  • Nola Research Works, LLC /ID# 153356
    New Orleans, Louisiana 70115, United States
  • Louisana Research Center, LLC /ID# 150446
    Shreveport, Louisiana 71105-6800, United States
  • University of Maryland Med Ctr /ID# 150449
    Baltimore, Maryland 21201, United States
  • Gastro Center of Maryland /ID# 200022
    Columbia, Maryland 21045, United States
  • Massachusetts General Hospital /ID# 165676
    Boston, Massachusetts 02114, United States
  • University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 151140
    Ann Arbor, Michigan 48109, United States
  • Huron Gastroenterology Assoc /ID# 152710
    Ann Arbor, Michigan 48197, United States
  • Clin Res Inst of Michigan, LLC /ID# 153027
    Chesterfield, Michigan 48047, United States
  • Revival Research Institute, LLC /ID# 207280
    Southfield, Michigan 48034-1659, United States
  • Center for Digestive Health /ID# 161984
    Troy, Michigan 48098-6363, United States
  • Gastroenterology Associates of Western Michigan, PLC d.b.a. West Michigan Clinic /ID# 157484
    Wyoming, Michigan 49519, United States
  • Mayo Clinic - Rochester /ID# 151677
    Rochester, Minnesota 55905-0001, United States
  • Minnesota Gastroenterology PA /ID# 151678
    Saint Paul, Minnesota 55114, United States
  • University of Mississippi Medical Center /ID# 213139
    Jackson, Mississippi 39216-4500, United States
  • Southern Therapy and Advanced Research (STAR) LLC /ID# 170712
    Jackson, Mississippi 39216, United States
  • Washington University-School of Medicine /ID# 150485
    Saint Louis, Missouri 63110, United States
  • Las Vegas Medical Research /ID# 153044
    Las Vegas, Nevada 89113, United States
  • Dartmouth-Hitchcock Medical Center /ID# 150549
    Lebanon, New Hampshire 03756, United States
  • AGA Clinical Research Associates, LLC /ID# 153040
    Egg Harbor Township, New Jersey 08234, United States
  • Atlantic Digestive Health Inst /ID# 150447
    Morristown, New Jersey 07960, United States
  • Rutgers Robert Wood Johnson /ID# 155248
    New Brunswick, New Jersey 08901, United States
  • Duplicate_University of New Mexico Department of Internal Medicine /ID# 214396
    Albuquerque, New Mexico 87131, United States
  • Montefiore Medical Center - Moses Campus /ID# 150543
    Bronx, New York 10467, United States
  • Advantage Clinical Trials /ID# 163938
    Bronx, New York 10468, United States
  • NY Scientific /ID# 152707
    Brooklyn, New York 11235, United States
  • NYU Langone Long Island Clinical Research Association /ID# 155272
    Great Neck, New York 11021, United States
  • Columbia Univ Medical Center /ID# 163410
    New York, New York 10032-3725, United States
  • DiGiovanna Institute for Medical Education & Research /ID# 201533
    North Massapequa, New York 11758, United States
  • Premier Medical Group - GI Division /ID# 153357
    Poughkeepsie, New York 12601, United States
  • Gastoenterology Group of Rochester /ID# 151079
    Rochester, New York 14618-5703, United States
  • Richmond University Medical Center /ID# 201859
    Staten Island, New York 10310-1664, United States
  • Digestive Health Partners, P.A /ID# 167237
    Asheville, North Carolina 28801, United States
  • Atrium Health Carolinas Medical Center /ID# 156971
    Charlotte, North Carolina 28203, United States
  • Charlotte Gastroenterology and Hepatology, PLLC /ID# 150545
    Charlotte, North Carolina 28207, United States
  • Atlantic Gastroenterology Clinical Research /ID# 151899
    Greenville, North Carolina 27834, United States
  • Clinical Trials of America /ID# 153448
    Winston-Salem, North Carolina 27103, United States
  • Wake Forest Baptist Medical Center /ID# 150448
    Winston-Salem, North Carolina 27157-0001, United States
  • Plains Clinical Research Center, LLC /ID# 170290
    Fargo, North Dakota 58104-5925, United States
  • Consultants for Clinical Research /ID# 151679
    Cincinnati, Ohio 45219, United States
  • University of Cincinnati /ID# 164582
    Cincinnati, Ohio 45267-0585, United States
  • The Ohio State University /ID# 169416
    Columbus, Ohio 43210, United States

Showing the first 100 of 496 sites across 46 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Danese S, Vermeire S, Zhou W, Pangan AL, Siffledeen J, Greenbloom S, Hebuterne X, D'Haens G, Nakase H, Panes J, Higgins PDR, Juillerat P, Lindsay JO, Loftus EV Jr, Sandborn WJ, Reinisch W, Chen MH, Sanchez Gonzalez Y, Huang B, Xie W, Liu J, Weinreich MA, Panaccione R. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022 Jun 4;399(10341):2113-2128. doi: 10.1016/S0140-6736(22)00581-5. Epub 2022 May 26. Erratum In: Lancet. 2022 Sep 24;400(10357):996. doi: 10.1016/S0140-6736(22)01069-8. PubMed 35644166 ↗
  • Sandborn WJ, Ghosh S, Panes J, Schreiber S, D'Haens G, Tanida S, Siffledeen J, Enejosa J, Zhou W, Othman AA, Huang B, Higgins PDR. Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis. Gastroenterology. 2020 Jun;158(8):2139-2149.e14. doi: 10.1053/j.gastro.2020.02.030. Epub 2020 Feb 22. Erratum In: Gastroenterology. 2020 Sep;159(3):1192. doi: 10.1053/j.gastro.2020.08.040. PubMed 32092309 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing, please refer to the link below.

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2016 to primary completion in Dec 2021, 62 months.

Results were first posted in Jun 2022, 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2016
First posted
Jun 30, 2016
StartActual
Sep 26, 2016
Primary completionActual
Dec 13, 2021
CompletionActual
Dec 13, 2021
Results first posted
Jun 30, 2022
Last update
Jun 30, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02819635
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jun 30, 2016
Start date
Sep 26, 2016
Primary completion
Dec 13, 2021
Completion
Dec 13, 2021
Results posted
Jun 30, 2022
Last update
Jun 30, 2022

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Upadacitinib

Start the discussion